Patent Grant
10773074
A portion of the material in this patent document is subject to copyright protection under the copyright laws of the United States and of other countries. The owner of the copyright rights has no objection to the facsimile reproduction by anyone of the patent document or the patent disclosure, as it appears in the United States Patent and Trademark Office publicly available file or records, but otherwise reserves all copyright rights whatsoever. The copyright owner does not hereby waive any of its rights to have this patent document maintained in secrecy, including without limitation its rights pursuant to 37 C.F.R. § 1.14.
Recovery of locomotion from permanent paralysis caused by spinal cord injuries (SCI) is one of the biggest topics in spinal cord prosthesis. It is known that networks of neurons in the lumbosacral spinal cord retain an intrinsic capability to oscillate and generate coordinated rhythmic motor outputs Circuits underlying such rhythmic and oscillatory outputs are commonly referred as central pattern generators (CPGs) (Grinner (2006) Neuron, 52: 751-766). Studies have demonstrated that animals can regain motor control from the plasticity of the spinal cord (Lavrov et al. (2006) J. Neurophysiol. 96: 1699-1710), and regain movements including, but not limited to, stepping and standing by stimulating the CPGs without control from the brain (Gad et al. (2013) J. Neuroengin. & Rehabil., 10: 2).
To provide the stimulus patterns into the spinal cord, various electrode arrays have been developed (see, e.g., Gad et al. (2013) J. Neuroengin. & Rehabil., 10: 2; Nandra et al. (2011). A parylene-based microelectrode array implant for spinal cord stimulation in rats,” in Micro Electro Mechanical Systems (MEMS), 2011 IEEE 24th International Conference, pp. 1007-1010).
Improved electrode arrays for spinal cord stimulation are provided that enough mechanical flexibility and durability function over long time periods in vivo while delivering electrical stimulation to the spinal cord at relatively high voltage and/or current. The electrode arrays are flexible and can tolerate movements after implantation and provide selectable/programmable multi-site electrodes to obtain the optimal stimulation parameters.
Various embodiments contemplated herein may include, but need not be limited to, one or more of the following:
An electrode array for epidural stimulation of the spinal cord, said array comprising: a plurality of electrodes disposed on a flexible polymer substrate; said electrodes being electrically connected to one or more lead wires and/or connection points on an electrical connector; wherein the electrodes of said array are bonded to said polymer so that the electrodes can carry an electrical stimulation signal having a voltage, frequency, and current sufficient to provide epidural stimulation of a spinal cord and/or brain in vivo or in a physiological saline solution, without separation of all or a part of an electrode from the polymer substrate.
The electrode array of embodiment 1, wherein said array is configured so that the electrodes can carry an electrical stimulation signal having a voltage, frequency, and current sufficient to provide epidural stimulation of a spinal cord over a period of at least 1 day, or over a period of at least 3 days, or over a period of at least one week, or over a period of at least two weeks, or over a period of at least one month, or over a period of at least two months, or over a period of at least 3 months, or over a period of at least 6 months, or over a period of at least 1 year in vivo or in a physiological saline solution, without separation of all or a part of an electrode from the polymer substrate.
The electrode array according to any one of embodiments 1-2, wherein said polymer includes a polymer selected from the group consisting of polyimide, parylene, PVC, polyethylene, PEEK, polycarbonate, Ultem PEI, polysulfone, polypropylene, silicone, and polyurethane.
The electrode array of embodiment 3, wherein said polymer includes polyimide or parylene.
The electrode array according to any one of embodiments 1-4, wherein said electrodes comprise one or more metals selected from the group consisting of platinum, titanium, chromium, tungsten, gold, and/or oxides and/or alloys thereof.
The electrode array of embodiment 5, wherein said electrode array includes platinum and/or titanium.
The electrode array according to any one of embodiments 1-6, wherein said electrodes comprise two layers, each layer comprising a different metal.
The electrode array according to any one of embodiments 1-7, wherein the thickness of the electrodes or the thickness of each layer comprising the electrodes when multiple layers are present ranges from about 1 nm, or from about 2 nm or from about 5 nm, or from about 10 nm up to about 1000 nm, or up to about 800 nm, or up to about 600 nm, or up to about 500 nm, or up to about 400 nm, or up to about 300 nm, or up to about 200 nm, or up to about 100 nm.
The electrode array according to any one of embodiments 7 to 8, wherein the first layer of said electrode ranges from about 2 nm up to about 20 nm, and the second layer of said electrode ranges from about 50 nm to about 250 nm.
The electrode array of embodiment 9, wherein the first layer of said electrode is about 10 nm in thickness and the second layer of said electrode is about 200 nm in thickness.
The electrode array according to any one of embodiments 1-10, wherein each electrode comprising a plurality of electrodes comprising said array is individually connected to a corresponding connection point on an electrical connector.
The electrode array according to any one of embodiments 1-11, wherein electrodes comprising said electrode array are disposed between a said polymer substrate and a second polymer layer, said second polymer layer comprising a plurality of openings through which said electrodes are exposed.
The electrode array of embodiment 12, wherein said plurality of openings includes a regular array (columns and rows) of openings.
The electrode array of embodiment 12, wherein said plurality of openings includes an array forming an interlaced pattern of openings.
The electrode array according to any one of embodiments 12-14, wherein openings comprising said plurality of openings are substantially the same size.
The electrode array according to any one of embodiments 12-14, wherein openings comprising said plurality of openings vary in size.
The electrode array according to any one of embodiments 12-14, wherein groups of said openings are localized over each electrode.
The electrode array of embodiment 17, wherein the openings localized over each electrode comprise a large opening disposed over the electrode, surrounded by smaller openings.
The electrode array according to any one of embodiments 12-18, wherein the openings comprising said plurality of openings range in average diameter from about 2 μm up to about 500 μm, or up to about 400 μm, or up to about 300 μm, or up to about 250 μm, or up to about 100 μm, or from about 5 μm up to about 100 μm or about 80 μm or about 60 μm, or from about 10 μm up to about 50 μm, or from about 15 μm up to about 50 μm, or from about 20 μm up to about 45 μm or 50 μm, or from about 25 μm up to about 45 μm or 50 μm, or from about 30 μm up to about 45 μm or 50 μm, or from about 35 μm up to about 45 μm or 50 μm.
The electrode array according to any one of embodiments 12-19, wherein electrodes comprising said array protrude above the top surface of said second polymer layer.
The electrode array according to any one of embodiments 12-19, wherein electrodes comprising said array are disposed lower than the top surface of said second polymer layer.
The electrode array according to any one of embodiments 12-19, wherein electrodes comprising said array are substantially even with top surface of said second polymer layer.
The electrode array according to any one of embodiments 12-22, wherein a silicon dioxide layer is present on top of said second polymer layer.
The electrode array according to any one of embodiments 1-23, wherein the electrode surfaces are roughened to provide a surface area that is at least 2× the projected surface area, or at least 3× the projected surface area, or about 3.8× the projected surface area.
The electrode array according to any one of embodiments 1-24, wherein the thickness of said polymer substrate ranges from about 1 μm or from about 2 μm, or from about 5 μm up to hundreds of μm (e.g., up to about 900 μm, or up to about 800 μm, or up to about 700 μm, or up to about 600 μm, or up to about 500 μm, or up to about 400 μm, or up to about 300 μm, or up to about 200 μm, or up to about 100 μm.
The electrode array according to any one of embodiments 12-25, wherein the thickness of said second polymer substrate ranges from about 1 μm or from about 2 μm, or from about 5 μm up to hundreds of μm (e.g., up to about 900 μm, or up to about 800 μm, or up to about 700 μm, or up to about 600 μm, or up to about 500 μm, or up to about 400 μm, or up to about 300 μm, or up to about 200 μm, or up to about 100 μm.
The electrode array according to any one of embodiments 1-26, wherein said electrode array includes: a substantially continuous polyimide polymer substrate; a plurality of electrodes said electrodes comprising a first layer of titanium and a second layer of platinum disposed on top of said polymer substrate; a second polyimide polymer layer disposed on top of said electrodes, where said second polyimide layer includes a plurality of openings through which said electrodes are exposed.
The electrode array of embodiment 27, wherein said polymer substrate and said second polymer layer range in thickness from about 4 μm to about 8 μm, or from about 4 μm to about 6 μm.
The electrode array according to any one of embodiments 1-28, wherein said array includes at least about 6 different electrodes, or at least about 8 different electrodes, or at least about 12 different electrodes, or at least about 15 different electrodes, or at least about 18 different electrodes, or at least about 27 different electrodes, or at least about 36 different electrodes.
The electrode array according to any one of embodiments 1-29, wherein the electrodes comprising said array are disposed in a substantially regular array pattern.
The electrode array according to any one of embodiments 1-29, wherein the electrodes comprising said array are disposed in an interlaced array pattern.
The electrode array according to any one of embodiments 1-31, wherein electrodes comprising said array are spaced along a longitudinal axis by a distance ranging from about 0.5 mm up to about 6 mm, or from about 1 mm up to about 5 mm, or from about 2 mm up to about 4 mm, or by a distance of about 3 mm.
The electrode array according to any one of embodiments 1-32, wherein the contact surfaces of electrodes comprising said array, are substantially regular polygons and have an average maximum diameter ranging from about 3 μm up to about 150 μm, or from about 5 μm up to about 100 μm, or from about 5 μm up to about 80 μm, or from about 5 μm up to about 60 μm, or from about 10 μm up to about 50 μm, or from about 15 μm up to about 50 μm, or from about 20 μm up to about 45 μm or 50 μm, or from about 25 μm up to about 45 μm or 50 μm, or from about 30 μm up to about 45 μm or 50 μm, or from about 35 μm up to about 45 μm or 50 μm; or the contact surfaces of electrodes comprising said array, have a major and minor axis where the dimensions of the major and minor axis independently range from about 3 μm up to about 150 μm, or from about 5 μm up to about 100 μm, or from about 5 μm up to about 80 μm, or from about 5 μm up to about 60 μm, or from about 10 μm up to about 50 μm, or from about 15 μm up to about 50 μm, or from about 20 μm up to about 45 μm or 50 μm, or from about 25 μm up to about 45 μm or 50 μm, or from about 30 μm up to about 45 μm or 50 μm, or from about 35 μm up to about 45 μm or 50 μm.
The electrode of embodiment 33, wherein the contact surface of electrodes comprising said array is substantially rectangular.
The electrode of embodiment 34, wherein the contact surface of electrodes comprising said array is about 0.5 mm by 0.2 mm.
The electrode array according to any one of embodiments 1-35, wherein the effective area factor of electrodes comprising said array is at least about 2.
The electrode array according to any one of embodiments 1-36, wherein the impedence of said electrode array at 1 KHz is no more than about 5K ohm.
The electrode array according to any one of embodiments 1-37, wherein the phase at 1 KHz is no more than 50 degrees.
The electrode array according to any one of embodiments 1-38, wherein the DL capacitance is at least about 50 nF.
The electrode array according to any one of embodiments 1-39, wherein the CT resistance is no more than about 100K ohm.
The electrode array according to any one of embodiments 1-40, wherein the tissue resistance is no more than about 5K ohm.
The electrode array according to any one of embodiments 1-41, wherein said electrode array provides channel isolation of at least about −20 dB.
The electrode array according to any one of embodiments 1-42, wherein electrodes comprising said electrode array are spaced along a longitudinal axis by a distance ranging from about 0.2 mm up to about 15 mm, or from about 0.5 mm up to about 10 mm, or from about 0.5 mm up to about 6 mm, or from about 1 mm up to about 5 mm, or from about 2 mm up to about 4 mm, or by a distance of about 3 mm.
The electrode array according to any one of embodiments 1-43, wherein said polymer substrate includes suture holes for fastening the array to a biological tissue.
An electrode array assembly, said assembly comprising a plurality of electrode arrays according to any one of embodiments 1-44.
The assembly of embodiment 45, wherein said electrode arrays are physically coupled.
The assembly of embodiment 45, wherein said electrode arrays are electrically coupled.
A system for simulation of the spinal cord and/or brain, said system comprising: an electrode array according to any one of embodiments 1-44 or an electrode array assembly according to any one of embodiments 45-47; and an electrical stimulator configured to deliver epidural stimulation of the brain or spinal cord through one or more electrodes comprising said electrode array or electrode array assembly.
The system of embodiment 48, wherein said system is configured to provide epidural stimulation at a frequency ranging from about 0.1 Hz or from about 0.5 Hz, or from about 1 Hz, or from about 2 Hz, or from about 3 Hz, or from about 5 Hz, or from about 10 Hz up to about 100 Hz, or up to about 80 Hz, or up to about 40 Hz, or from about 0.1 Hz up to about 100 Hz, or from about 1 Hz, or from about 3 Hz or from about 5 Hz up to about 80 Hz, or from about 5 Hz up to about 30 Hz, or up to about 40 Hz, or up to about 50 Hz, or up to about 100 Hz.
The system according to any one of embodiments 48-49, wherein said system is configured to provide epidural stimulation at an amplitude ranging from 0.05 mA to about 30 mA, or from about 0.1 mA to about 20 mA, or from about 0.1 mA to about 15 mA or to about 10 mA.
The system according to any one of embodiments 48-50, wherein system is configured to provide a pulse width that ranges from about 50 μs up to about 100 μs or up to about 1000 μs, from about 150 μs up to about 600 μs, or from about 200 μs to about 500 μs, or from about 200 μs to about 450 μs, or from about 100 μs up to about 1000 μs.
The system according to any one of embodiments 48-51, wherein said system is configured to provide epidural stimulation at a frequency and amplitude sufficient to stimulate or to improve postural and/or locomotor activity and/or postural or locomotor strength.
The system according to any one of embodiments 48-52, wherein said system is configured to provide epidural stimulation at a frequency and amplitude sufficient to stimulate or to improve upper extremity motion, and/or hand motion, and/or gripping, and/or grasping, and/or reaching, and/or pulling, and/or pushing.
The system according to any one of embodiments 48-53, wherein said system is configured to provide epidural stimulation at a frequency and amplitude sufficient to stimulate or improve autonomic function.
The system according to any one of embodiments 48-54, wherein said system is configured to provide epidural stimulation at a frequency and amplitude sufficient to stimulate or improve voluntary voiding of the bladder and/or bowel, and/or return of sexual function, and/or autonomic control of cardiovascular function, and/or body temperature.
The system according to any one of embodiments 48-55, wherein said system is configured to provide epidural stimulation at a frequency and amplitude sufficient to stimulate or improve ventilation, and/or swallowing, and/or chewing, and/or speaking, and/or cognitive function.
A method of stimulating or improving postural and/or locomotor activity and/or postural or locomotor strength; and/or improving motor control and/or strength in a hand and/or upper limb of a subject with a neuromotor disorder affecting motor control of the hand and/or upper limb; and/or enabling or improving one or more functions selected from the group consisting of voluntary voiding of the bladder and/or bowel, return of sexual function, autonomic control of cardiovascular function, respiration, kidney function, digestion, and control of body temperature, in a subject having a neurologically derived paralysis, said method comprising neuromodulating the spinal cord of said subject or a region thereof by administering epidural stimulation to the spinal cord or a region thereof using an electrical stimulator electrically coupled to an electrode array according to any one of embodiments 1-44 or an electrode assembly according to any one of embodiments 45-47 implanted in the brain and/or over the spinal cord or a region thereof.
The method of embodiment 57, wherein said epidural stimulation is at a frequency ranging from about 0.1 Hz or from about 0.5 Hz, or from about 1 Hz, or from about 2 Hz, or from about 3 Hz, or from about 5 Hz, or from about 10 Hz up to about 100 Hz, or up to about 80 Hz, or up to about 40 Hz, or from about 0.1 Hz up to about 100 Hz, or from about 1 Hz, or from about 3 Hz or from about 5 Hz up to about 80 Hz, or from about 5 Hz to about 30 Hz, or to about 40 Hz, or to about 50 Hz, or up to about 100 Hz.
The method according to any one of embodiments 57-58, wherein said epidural stimulation is at an amplitude ranging from 0.05 mA to about 30 mA, or from about 0.1 mA to about 20 mA, or from about 0.1 mA to about 15 mA or to about 10 mA.
The method according to any one of embodiments 57-59, wherein said pulse width ranges from about 50 μs up to about 1000 μs, from about 150 μs up to about 600 μs, or from about 200 μs to about 500 μs, or from about 200 μs to about 450 μs, or about 100 μs up to about 1000 μs.
The method according to any one of embodiments 57-60, wherein said epidural stimulation is at a frequency and amplitude sufficient to stimulating or improving postural and/or locomotor activity and/or postural or locomotor strength.
The method according to any one of embodiments 57-61, wherein said system is configured to provide epidural stimulation at a frequency and amplitude sufficient to stimulate or to improve upper extremity motion, and/or hand motion, and/or gripping, and/or grasping, and/or reaching, and/or pulling, and/or pushing.
The method according to any one of embodiments 57-62, wherein said system is configured to provide epidural stimulation at a frequency and amplitude sufficient to stimulate or improve autonomic function.
The method according to any one of embodiments 57-63, wherein said system is configured to provide epidural stimulation at a frequency and amplitude sufficient to stimulate or improve voluntary voiding of the bladder and/or bowel, and/or return of sexual function, and/or autonomic control of cardiovascular function, and/or body temperature.
The method according to any one of embodiments 57-64, wherein said system is configured to provide epidural stimulation at a frequency and amplitude sufficient to stimulate or improve ventilation, and/or swallowing, and/or chewing, and/or speaking, and/or cognitive function.
The method according to any one of embodiments 57-65, wherein said epidural stimulation is applied paraspinally over vertebrae comprising the cervical spine, brain stem, or a region thereof.
The method according to any one of embodiments 57-65, wherein said epidural stimulation is applied paraspinally vertebrae comprising the thoracic spine or a region thereof.
The method according to any one of embodiments 57-65, wherein said epidural stimulation is applied paraspinally over a region of the thoracic spine comprising T11-T12.
The method according to any one of embodiments 57-65, wherein said epidural stimulation is applied paraspinally over vertebrae comprising the lumbar spine, or lumbar sacral spine, or a region thereof.
The method according to any one of embodiments 57-65, wherein said epidural stimulation is applied paraspinally over a region of the spinal cord that controls the lower limbs or the upper limbs to stimulate or improve postural and/or locomotor activity and/or postural or locomotor strength.
The method of embodiment 70, wherein said locomotor activity includes standing and/or stepping.
The method of embodiment 70, wherein said locomotor activity includes sitting down or laying down.
The method of embodiment 70, wherein said the movement includes reaching, grasping and/or stabilizing sitting or standing posture.
The method according to any one of embodiments 57-61, wherein said method is a method of improving motor control and/or strength in a hand and/or upper limb of a subject with a neuromotor disorder affecting motor control of the hand and/or upper limb.
The method of embodiment 74, wherein said epidural stimulation is at a frequency and amplitude sufficient to improve hand strength and/or fine hand control.
The method according to any one of embodiments 74-75, wherein said epidural stimulation is applied paraspinally over the brainstem or vertebrae spanning C2 to T1.
The method according to any one of embodiments 74-75, wherein said epidural stimulation is applied paraspinally over vertebrae spanning C5 to T1.
The method according to any one of embodiments 57-77, wherein said method further includes physical training of said subject.
The method of embodiment 78, wherein said method includes subjecting said subject to physical training that exposes said subject to relevant postural, touch, movement, and/or locomotor proprioceptive signals.
The method according to any one of embodiments 78-79, wherein the combination of said stimulation and physical training modulates in real time the electrophysiological properties of spinal circuits in said subject activated by proprioceptive information derived from the region of the subject where said previously stated functions are facilitated.
The method according to any one of embodiments 78-80, wherein said physical training includes inducing a load bearing positional change in the region of the subject where locomotor activity is to be facilitated.
The method according to any one of embodiments 78-81, wherein said physical training includes movements of the lower limbs with or without resistance, and/or standing, and/or trunk control.
The method of embodiment 81, wherein the load bearing positional change in said subject includes standing.
The method of embodiment 81, wherein the load bearing positional change in said subject includes stepping.
The method of embodiment 81, wherein the load bearing positional change in said subject includes reaching.
The method of embodiment 81, wherein the load bearing positional change in said subject includes grasping and/or pulling, and/or pushing.
The method according to any one of embodiments 78-81, wherein said physical training includes hand contraction and/or upper limb movements against a resistance.
The method according to any one of embodiments 78-81, wherein said physical training includes tracing a displayed pattern by hand manipulation of a hand controller.
The method according to any one of embodiments 78-88, wherein said physical training includes robotically guided training.
The method according to any one of embodiments 78-89, wherein said physical training includes induced movement.
The method of embodiment 90, wherein said induced movement includes ventilation (induced breathing).
The method according to any one of embodiments 57-91, wherein said epidural stimulation is applied paraspinally over a region of the spinal cord that controls the bladder and/or bowel, and/or breathing, and/or sexual function, and/or chewing, and/or swallowing, and/or blood pressure, and/or body temperature, and/or digestion, and/or kidney function.
The method according to any one of embodiments 57-92, wherein one or more electrodes comprising said array are stimulated in a monopolar configuration.
The method according to any one of embodiments 57-92, wherein one or more electrodes comprising said array are stimulated in a bipolar configuration.
The method according to any one of embodiments 57-94, wherein one or more electrodes comprising said array are stimulated in a monophasic mode.
The method according to any one of embodiments 57-94, wherein one or more electrodes comprising said array are stimulated in a biphasic mode.
The method according to any one of embodiments 57-96, wherein said stimulation includes tonic stimulation.
The method according to any one of embodiments 57-97, wherein said stimulation includes simultaneous, synchronous, sequential or alternating stimulation of different spinal cord regions and/or of different electrodes or groups of electrodes.
The method according to any one of embodiments 57-98, wherein the stimulation pattern is under control of the subject.
The method according to any one of embodiments 57-99, wherein the stimulation pattern is remotely controlled wirelessly and/or over the internet (e.g., by a clinical person skilled in the art).
The method according to any one of embodiments 57-100, wherein said subject is administered at least one monoaminergic agonist.
The method of embodiment 101, wherein said at least one monoaminergic agonist includes an agent selected from the group consisting of a serotonergic drug, a dopaminergic drug, a noradrenergic drug, a GABAergic drug, and a glycinergic drug.
The method of embodiment 102, wherein said agent is selected from the group consisting of 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), 4-(benzodioxan-5-yl)1-(indan-2-yl)piperazine (S15535), N-{2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl}-N-(2-pyridinyl)cyclo-hexanecarboxamide (WAY 100.635), Quipazine, Ketanserin, 4-amino-(6-chloro-2-pyridyl)-1 piperidine hydrochloride (SR 57227A), Ondanesetron, Buspirone, Methoxamine, Prazosin, Clonidine, Yohimbine, 6-chloro-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diol (SKF-81297), 7-chloro-3-methyl-1-phenyl-1,2,4,5-tetrahydro-3-benzazepin-8-ol (SCH-23390), Quinpirole, and Eticlopride.
The method of embodiment 102, wherein said monoaminergic agonist is buspirone.
The method according to any one of embodiments 57-104, wherein said subject is a non-human mammal.
The method according to any one of embodiments 57-104, wherein said subject is a human.
The method according to any one of embodiments 57-106, wherein said subject has a spinal cord injury.
The method of embodiment 107, wherein said spinal cord injury is clinically classified as motor complete.
The method of embodiment 107, wherein said spinal cord injury is clinically classified as motor incomplete.
The method according to any one of embodiments 57-105, wherein said subject has an ischemic brain injury.
The method of embodiment 110, wherein said ischemic brain injury is brain injury from stroke or acute trauma.
The method according to any one of embodiments 57-105, wherein said subject has a neurodegenerative pathology.
The method of embodiment 112, wherein said neurodegenerative pathology is associated with a condition selected from the group consisting of stroke, Parkinson's disease, Huntington's disease, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), primary lateral sclerosis (PLS), dystonia, and cerebral palsy.
The method according to any one of embodiments 57-113, wherein said subject is suffering with chronic pain.
An apparatus for spinal-cord epidural stimulation, the apparatus comprising: an array of electrodes on a flexible polymer substrate; said electrode array comprising a plurality of suture holes; each electrode in the array of electrodes being individually connected to a corresponding connection point on an electrical connector; said array of electrodes configured for placement on the spinal cord and/or the brain within the epidural space; said suture holes configured to fix the array of electrodes onto the cover of the spinal cord (dura) and/or lower layer of the spinal bones.
The apparatus of embodiment 115, wherein the electrodes in the array are arranged in a matrix pattern.
The apparatus of embodiment 115, wherein the electrodes in the array are arranged in an interlaced pattern.
The apparatus of embodiment 115, wherein each electrode has a grid pattern.
The apparatus of embodiment 115, wherein each electrode has a rectangular size of approximately 0.5 mm by 0.2 mm.
The apparatus of embodiment 116, wherein: each electrode has a rectangular size of approximately 0.5 mm by 0.2 mm; each electrode is spaced apart along a longitudinal axis by approximately 3 mm; and each electrode is spaced apart along a lateral axis by approximately 1 mm.
The apparatus of embodiment 117, wherein: each electrode has a rectangular size of approximately 0.5 mm by 0.2 mm; and each electrode is spaced apart along a longitudinal axis by approximately 1.5 mm.
A method of making an electrode array for epidural stimulation of the spinal cord, said array comprising a plurality of electrodes disposed on a flexible polymer substrate, said method comprising: depositing a polymer layer on a support surface and curing said polymer layer to form a cured polymer layer; roughening the surface of said cured polymer layer; using vapor deposition and lift off to deposit metal, metal alloy, and/or metal oxide electrode layers and to define a plurality of electrodes; depositing a second polymer layer on said electrodes and curing said polymer layer to form a second cured polymer layer; depositing a silicon dioxide film on said second polymer layer and defining features in said film using a reactive ion etch with a plasma etcher; coating a positive photoresist coating onto the exposed surface; creating the electrode contact pattern using microphotolithography; using an oxygen plasma process to define the shape of the electrode array as well as exposing the contact metal layer of electrodes and connector pads; performing an oxygen/CF4 RIE to roughing the contact surface of the electrodes; and detaching the electrode array from the support surface.
The method of embodiment 122, further comprising attaching electrical correctors to the array electrodes.
The method according to any one of embodiments 122-123 further comprising silicon encapsulation of all soldered parts.
The method according to any one of embodiments 122-124, wherein said polymer includes a polymer selected from the group consisting of polyimide, parylene, PVC, polyethylene, PEEK, polycarbonate, Ultem PEI, polysulfone, polypropylene, silicone, and polyurethane.
The method according to any one of embodiments 122-124, wherein said polymer includes polyimide, parylene, or silicone.
The method of embodiment 126, wherein said polymer is polyimide.
The method according to any one of embodiments 122-127, wherein the polymer layer is deposited by spin coating.
The method according to any one of embodiments 122-128, wherein said electrodes comprise a first layer of titanium underlying a second layer of platinum.
The method according to any one of embodiments 122-129, wherein said support surface includes a handle silicon wafer.
The method of embodiment 130, wherein said silicon wafer has a chromium/aluminum layer deposited thereon.
The method of embodiment 131, wherein an adhesion promoter is deposited on said chromium/aluminum layer.
The method according to any one of embodiments 122-132, wherein said roughening the surface of said cured polymer layer is by use of an oxygen-plasma process.
The method according to any one of embodiments 122-133, when complete the electrodes of said array are bonded to said polymer so that the electrodes can carry an electrical stimulation signal having a voltage, frequency, and current sufficient to provide epidural stimulation of a spinal cord and/or brain in vivo or in a physiological saline solution, without separation of all or a part of an electrode from the polymer substrate.
The method according to any one of embodiments 122-134, where when complete said array is configured so that the electrodes can carry an electrical stimulation signal having a voltage, frequency, and current sufficient to provide epidural stimulation of a spinal cord over a period of at least one week, or over a period of at least two weeks, or over a period of at least one month, or over a period of at least two months, or over a period of at least 3 months, or over a period of at least 6 months, or over a period of at least 1 year in vivo or in a physiological saline solution, without separation of all or a part of an electrode from the polymer substrate.
The method according to any one of embodiments 122-135, wherein said electrode layers comprise one or more metals selected from the group consisting of platinum, titanium, chromium, tungsten, gold, and/or oxides and/or alloys thereof.
The method of embodiment 136, wherein said electrode layers comprise platinum and/or titanium.
The method according to any one of embodiments 122-137, wherein said electrodes comprise two layers, each layer comprising a different metal.
The method according to any one of embodiments 122-138, wherein when complete the thickness of the electrodes or the thickness of each layer comprising the electrodes when multiple layers are present ranges from about 1 nm, or from about 2 nm or from about 5 nm, or from about 10 nm up to about 1000 nm, or up to about 800 nm, or up to about 600 nm, or up to about 500 nm, or up to about 400 nm, or up to about 300 nm, or up to about 200 nm, or up to about 100 nm.
The method of embodiments 138-139, wherein when complete the first layer of said electrode ranges from about 2 nm up to about 20 nm, and the second layer of said electrode ranges from about 50 nm to about 250 nm.
The method of embodiment 140, wherein when complete the first layer of said electrode is about 10 nm in thickness and the second layer of said electrode is about 200 nm in thickness.
The method according to any one of embodiments 122-141, wherein when complete each electrode comprising a plurality of electrodes comprising said array is individually connected to a corresponding connection point on an electrical connector.
The method according to any one of embodiments 122-142, wherein when complete the electrodes comprising said electrode array are disposed between said polymer substrate and a second polymer layer, said second polymer layer comprising a plurality of openings through which said electrodes are exposed.
The method of embodiment 143, wherein said plurality of openings includes a regular array (columns and rows) of openings.
The method of embodiment 143, wherein said plurality of openings includes an array forming an interlaced pattern of openings.
The method according to any one of embodiments 143-145, wherein openings comprising said plurality of openings are substantially the same size.
The method according to any one of embodiments 143-145, wherein openings comprising said plurality of openings vary in size.
The method according to any one of embodiments 143-145, wherein groups of said openings are localized over each electrode.
The method of embodiment 148, wherein the openings localized over each electrode comprise a large opening disposed over the electrode, surrounded by smaller openings.
The method according to any one of embodiments 143-149, wherein the openings comprising said plurality of openings range in average diameter from about 2 μm up to about 500 μm, or up to about 400 μm, or up to about 300 μm, or up to about 250 μm, or up to about 100 μm, or from about 5 μm up to about 100 μm or about 80 μm or about 60 μm, or from about 10 μm up to about 50 μm, or from about 15 μm up to about 50 μm, or from about 20 μm up to about 45 μm or 50 μm, or from about 25 μm up to about 45 μm or 50 μm, or from about 30 μm up to about 45 μm or 50 μm, or from about 35 μm up to about 45 μm or 50 μm.
The method according to any one of embodiments 143-150, wherein electrodes comprising said array, when complete protrude above the top surface of said second polymer layer.
The method according to any one of embodiments 143-150, wherein electrodes comprising said array when complete are disposed lower than the top surface of said second polymer layer.
The method according to any one of embodiments 143-150, wherein electrodes comprising said array when complete are substantially even with top surface of said second polymer layer.
The method according to any one of embodiments 143-153, wherein a silicon dioxide layer is present on top of said second polymer layer.
The method according to any one of embodiments 122-154, wherein the electrode surfaces are roughened to provide a surface area that is at least 2× the projected surface area, or at least 3× the projected surface area, or about 3.8× the projected surface area.
The method according to any one of embodiments 122-155, wherein the thickness of said polymer substrate ranges from about 1 μm or from about 2 μm, or from about 5 μm up to hundreds of μm (e.g., up to about 900 μm, or up to about 800 μm, or up to about 700 μm, or up to about 600 μm, or up to about 500 μm, or up to about 400 μm, or up to about 300 μm, or up to about 200 μm, or up to about 100 μm.
The method according to any one of embodiments 143-156, wherein the thickness of said second polymer substrate ranges from about 1 μm or from about 2 μm, or from about 5 μm up to hundreds of μm (e.g., up to about 900 μm, or up to about 800 μm, or up to about 700 μm, or up to about 600 μm, or up to about 500 μm, or up to about 400 μm, or up to about 300 μm, or up to about 200 μm, or up to about 100 μm.
The method according to any one of embodiments 122-157, wherein said electrode array, when complete, includes: a substantially continuous polyimide polymer substrate; a plurality of electrodes said electrodes comprising a first layer of titanium and a second layer of platinum disposed on top of said polymer substrate; a second polyimide polymer layer disposed on top of said electrodes, where said second polyimide layer includes a plurality of openings through which said electrodes are exposed.
The method of embodiment 158, wherein said polymer substrate and said second polymer layer range in thickness from about 4 μm to about 8 μm, or from about 4 μm to about 6 μm.
The method according to any one of embodiments 122-159, wherein said array includes at least about 6 different electrodes, or at least about 8 different electrodes, or at least about 12 different electrodes, or at least about 15 different electrodes, or at least about 18 different electrodes, or at least about 27 different electrodes, or at least about 36 different electrodes.
The method according to any one of embodiments 122-160, wherein the electrodes comprising said array are disposed in a substantially regular array pattern.
The method according to any one of embodiments 122-160, wherein the electrodes comprising said array are disposed in an interlaced array pattern.
The method according to any one of embodiments 122-162, wherein electrodes comprising said array are spaced along a longitudinal axis by a distance ranging from about 0.5 mm up to about 6 mm, or from about 1 mm up to about 5 mm, or from about 2 mm up to about 4 mm, or by a distance of about 3 mm.
The method according to any one of embodiments 122-163, wherein the contact surfaces of electrodes comprising said array, are substantially regular polygons and have an average maximum diameter ranging from about 3 μm up to about 150 μm, or from about 5 μm up to about 100 μm, or from about 5 μm up to about 80 μm, or from about 5 μm up to about 60 μm, or from about 10 μm up to about 50 μm, or from about 15 μm up to about 50 μm, or from about 20 μm up to about 45 μm or 50 μm, or from about 25 μm up to about 45 μm or 50 μm, or from about 30 μm up to about 45 μm or 50 μm, or from about 35 μm up to about 45 μm or 50 μm; or the contact surfaces of electrodes comprising said array, have a major and minor axis where the dimensions of the major and minor axis independently range from about 3 μm up to about 150 μm, or from about 5 μm up to about 100 μm, or from about 5 μm up to about 80 μm, or from about 5 μm up to about 60 μm, or from about 10 μm up to about 50 μm, or from about 15 μm up to about 50 μm, or from about 20 μm up to about 45 μm or 50 μm, or from about 25 μm up to about 45 μm or 50 μm, or from about 30 μm up to about 45 μm or 50 μm, or from about 35 μm up to about 45 μm or 50 μm.
The method of embodiment 164, wherein the contact surface of electrodes comprising said array is substantially rectangular.
The method of embodiment 165, wherein the contact surface of electrodes comprising said array is about 0.5 mm by 0.2 mm.
The method according to any one of embodiments 122-166, wherein, when complete, the effective area factor of electrodes comprising said array is at least about 2.
The method according to any one of embodiments 122-167, wherein, when complete, the impedance of said electrode array at 1 KHz is no more than about 5K ohm.
The method according to any one of embodiments 122-168, wherein when complete the phase of said array at 1 KHz is no more than 50 degrees.
The method according to any one of embodiments 122-169, wherein when complete the DL capacitance is at least about 50 nF.
The method according to any one of embodiments 122-170, wherein when complete the CT resistance is no more than about 100K ohm.
The method according to any one of embodiments 122-171, wherein the tissue resistance of the complete array is no more than about 5K ohm.
The method according to any one of embodiments 122-172, wherein said electrode array provides channel isolation of at least about −20 dB.
The method according to any one of embodiments 122-173, wherein electrodes comprising said electrode array are spaced along a longitudinal axis by a distance ranging from about 0.2 mm up to about 15 mm, or from about 0.5 mm up to about 10 mm, or from about 0.5 mm up to about 6 mm, or from about 1 mm up to about 5 mm, or from about 2 mm up to about 4 mm, or by a distance of about 3 mm.
The method according to any one of embodiments 122-174, wherein said polymer substrate includes suture holes for fastening the array to a biological tissue.
As used herein “electrical stimulation” or “stimulation” means application of an electrical signal that may be either excitatory or inhibitory to a muscle, nerve, nerve body, nerve cell, neuron, and/or to groups of neurons and/or interneurons. It will be understood that an electrical signal may be applied to one or more electrodes with one or more return electrodes.
As used herein “epidural” means situated upon the dura or in very close proximity to the dura. The term “epidural stimulation” refers to electrical epidural stimulation with electrodes placed on or near the dura. In certain embodiments epidural stimulation is referred to as “electrical enabling motor control” (eEmc).
The term “motor complete” when used with respect to a spinal cord injury indicates that there is no motor function below the lesion, (e.g., no movement can be voluntarily induced in muscles innervated by spinal segments below the spinal lesion.
The term “monopolar stimulation” refers to stimulation between a local electrode and a common distant return electrode.
The term “co-administering”, “concurrent administration”, “administering in conjunction with” or “administering in combination” when used, for example with respect to transcutaneous electrical stimulation, epidural electrical stimulation, and pharmaceutical administration, refers to administration of the transcutaneous electrical stimulation and/or epidural electrical stimulation and/or pharmaceutical such that various modalities can simultaneously achieve a physiological effect on the subject. The administered modalities need not be administered together, either temporally or at the same site. In some embodiments, the various “treatment” modalities are administered at different times. In some embodiments, administration of one can precede administration of the other (e.g., drug before electrical stimulation or vice versa). Simultaneous physiological effect need not necessarily require presence of drug and the electrical stimulation at the same time or the presence of both stimulation modalities at the same time. In some embodiments, all the modalities are administered essentially simultaneously.
In certain embodiments novel flexible electrode arrays are provided. The electrode arrays offer a plurality of electrodes disposed on a flexible polymer substrate and can readily be utilized to deliver epidural (or other) electrical stimulation.
Unlike other polymer-based electrode arrays, the present electrode arrays are fabricated in a manner that permits the arrays to be used at high voltage and current over long periods of time without the metal electrodes separating from the polymer substrate. In particular, in various embodiments, the electrodes of the array are bonded to the polymer substrate so that the electrodes can carry an electrical stimulation signal having a voltage, frequency, and current sufficient to provide epidural stimulation of a spinal cord in vivo (or can maintain similar voltage, frequency, and current in a physiological saline solution) without separation of all or a part of an electrode from the polymer substrate. In certain embodiments the array is configured so that the electrodes can carry an electrical stimulation signal having a voltage, frequency, and current sufficient to provide epidural stimulation of a spinal cord over a period of at least one week, or over a period of at least two weeks, or over a period of at least one month, or over a period of at least two months, or over a period of at least 3 months, or over a period of at least 6 months, or over a period of at least 1 year in vivo or in a physiological saline solution, without separation of all or a part of an electrode from the polymer substrate.
Additionally, the electrode arrays offer a high double layer capacitance and therefore enhanced the charge transfer capability coupled with a low charge transfer resistance and good channel isolation. Accordingly, in view of the high mechanical stability/durability and desirable electrical characteristics, the electrode arrays described herein are well suited for prolonged in vivo use, for example, as implants to facilitate epidural stimulation of the spinal cord and/or regions thereof. The electrode arrays are well suited for use in electrical stimulation systems to provide recovery of function in subjects with a neurological impairment (e.g., subjects with brain and/or spinal cord trauma), and/or physiological impairment (e.g., subjects with bladder dysfunction).
In certain embodiments the electrode array comprises a plurality of electrodes disposed on a flexible polymer substrate, where the electrodes are electrically connected to one or more connection points on an electrical connector and electrodes comprising the array are bonded to the polymer so that the electrodes can carry an electrical stimulation signal having a voltage, frequency, and current sufficient to provide epidural stimulation of a spinal cord in vivo (or similar voltage, frequency, and current in a physiological saline solution), without separation of all or a part of an electrode from the polymer substrate.
In certain embodiments the electrode array comprises a plurality of electrodes disposed on a flexible polymer substrate, where the electrodes are electrically connected to one or more connection points on an electrical connector and electrodes comprising the array are bonded to the polymer so that the electrodes can receive an electrical signal from the spinal cord, spinal nerve, nerve root, and/or surrounding area in vivo, without separation of all or a part of the electrode from the polymer substrate.
The polymer substrate can comprise any of a number of polymers. In certain embodiments the polymers are physiologically compatible polymers and/or polymers that have been approved by the U.S. Food and Drug Administration for implantation within a human body. In certain embodiments the polymer comprises a polymer selected from the group consisting of polyimide, parylene, PVC, polyethylene, PEEK, polycarbonate, Ultem PEI, polysulfone, polypropylene, polydimethylsiloxane, silicone, and polyurethane. In certain embodiments the polymer is polyimide, parylene, or silicone. In certain embodiments the thickness of the polymer substrate ranges from about 1 μm or from about 2 μm, or from about 5 μm up to hundreds of μm (e.g., up to about 900 μm, or up to about 800 μm, or up to about 700 μm, or up to about 600 μm, or up to about 500 μm, or up to about 400 μm, or up to about 300 μm, or up to about 200 μm, or up to about 100 μm. In certain embodiments, the thickness of the polymer substrate ranges from about 1 μm, or from about 2 μm, or from about 3 μm, or from about 4 μm, or from about 5 μm up to about 100 μm, or up to about 50 μm, or up to about 40 μm, or up to about 30 μm, or up to about 20 μm, or up to about 15 μm, or up to about 10 μm, or up to about 15 μm, or up to about 20 μm, or up to about 25 μm.
In various embodiments the electrodes are fabricated from one or more electrically conductive materials, e.g., a metal, metal alloy, metal oxide, etc. In certain embodiments the electrodes comprise one or more materials selected from the group consisting of platinum, titanium, chromium, iridium, tungsten, gold, carbon-nanotubes, stainless steel, silver, silver chloride, indium tin oxide (ITO), conductive polymers (Polypyrrole (Ppy) or poly-3,4-ethylenedioxythiophene (PEDOT)) and/or their oxides and/or alloys thereof. In certain embodiments the electrodes comprises platinum and/or titanium.
In various embodiments the electrodes are fabricated from a single material layer. In certain embodiments the electrodes comprise two layers, each layer comprising a different metal, alloy, or oxide. In one illustrative, but non-limiting embodiment the electrodes comprise a layer of titanium and a layer of platinum.
In certain embodiments the thickness of the electrodes or the thickness of each layer comprising the electrodes when multiple layers are present ranges from about 1 nm, or from about 2 nm or from about 5 nm, or from about 10 nm up to about 1000 nm, or up to about 800 nm, or up to about 600 nm, or up to about 500 nm, or up to about 400 nm, or up to about 300 nm, or up to about 200 nm, or up to about 100 nm. In certain embodiments, where two layers are present, the first layer of the electrode ranges from about 1 nm up to about 1000 nm, or from about 1 nm or about 2 nm up to about 500 nm, or from about 1 nm or about 2 nm up to about 250 nm, or from about 1 nm or about 2 nm up to about 100 nm, or from about 1 or about 2 nm up to about 50 nm, or from about 1 nm or about 2 nm up to about 20 nm, and the second layer of said electrode ranges ranges from about 1 nm up to about 1000 nm, or from about 1 nm or about 2 nm up to about 500 nm, or from about 1 nm or about 2 nm up to about 250 nm, or from about 1 nm or about 2 nm up to about 100 nm, or from about 1 or about 2 nm up to about 50 nm, or from about 1 nm or about 2 nm up to about 20 nm. In certain embodiments the first layer of the electrode is about 10 nm in thickness and the second layer of said electrode is about 200 nm in thickness.
In certain embodiments each electrode comprising a plurality of electrodes comprising the array is individually connected (e.g., electrically coupled) to a corresponding connection point on an electrical connector. In certain embodiments multiple electrodes comprising the array are connected to a common connection point on an electrical connector.
In certain embodiments electrodes comprising said electrode array are disposed between the polymer substrate, and a second polymer layer, said second polymer layer comprising a plurality of openings through which the electrodes (electrode contact surfaces) are exposed. In certain embodiments the plurality of openings comprises a regular array (columns and rows) of openings or an an interlaced pattern of openings (see, e.g.,
In various embodiments the openings can be shaped like substantially regular polygons (e.g., circles, squares, hexagons, etc.) while in other embodiments, the openings can be characterized by a major and minor axis (e.g., rectangles, ovoids, etc.). In certain embodiments, the openings can be irregular. In certain embodiments the openings range in average diameter (or average characteristic dimension) from about 2 μm up to about 500 μm, or up to about 400 μm, or up to about 300 μm, or up to about 250 μm, or up to about 100 μm, or from about 5 μm up to about 100 μm or about 80 μm or about 60 μm, or from about 10 μm up to about 50 μm, or from about 15 μm up to about 50 μm, or from about 20 μm up to about 45 μm or 50 μm, or from about 25 μm up to about 45 μm or 50 μm, or from about 30 μm up to about 45 μm or 50 μm, or from about 35 μm up to about 45 μm or 50 μm. In certain embodiments the major axis and minor axis independently (subject to remaining major and minor respectively) range from about 3 μm up to about 150 μm, or from about 5 μm up to about 100 μm, or from about 5 μm up to about 80 μm, or from about 5 μm up to about 60 μm, or from about 10 μm up to about 50 μm, or from about 15 μm up to about 50 μm, or from about 20 μm up to about 45 μm or 50 μm, or from about 25 μm up to about 45 μm or 50 μm, or from about 30 μm up to about 45 μm or 50 μm, or from about 35 μm up to about 45 μm or 50 μm.
In certain embodiments the electrodes comprising the electrode array protrude above the top surface of the second polymer layer (see, e.g.,
In certain embodiments a silicon dioxide layer is optionally present on top of the second polymer layer.
In certain embodiments the electrode surfaces are roughened to provide a surface area that is at least 2× the projected surface area, or at least 3× the projected surface area, or about 3.8× the projected surface area. In various embodiments the electrode surface can be convex (see, e.g.,
In certain embodiments the thickness of said second polymer layer ranges about 1 μm or from about 2 μm, or from about 5 μm up to hundreds of μm (e.g., up to about 900 μm, or up to about 800 μm, or up to about 700 μm, or up to about 600 μm, or up to about 500 μm, or up to about 400 μm, or up to about 300 μm, or up to about 200 μm, or up to about 100 μm. In certain embodiments, the thickness of the polymer substrate ranges from about 1 μm, or from about 2 μm, or from about 3 μm, or from about 4 μm, or from about 5 μm up to about 100 μm, or up to about 50 μm, or up to about 40 μm, or up to about 30 μm, or up to about 20 μm, or up to about 15 μm, or up to about 10 μm, or up to about 15 μm, or up to about 20 μm, or up to about 25 μm.
In certain embodiments the electrode array comprises a substantially continuous polyimide polymer substrate; a plurality of electrodes the electrodes comprising a first layer of titanium and a second layer of platinum disposed on top of the polymer substrate; a second polyimide polymer layer disposed on top of the electrodes, where the second polyimide layer comprises a plurality of openings through which the electrodes are exposed. In certain embodiments the polymer substrate and the second polymer layer range in thickness from about 4 μm to about 8 μm, or from about 4 μm to about 6 μm.
The electrode array comprises at least 2 different electrodes or at least about 4 different electrodes, or at least about 6 different electrodes, or at least about 8 different electrodes, or at least about 12 different electrodes, or at least about 15 different electrodes, or at least about 18 different electrodes, or at least about 27 different electrodes, or at least about 36 different electrodes. In certain embodiments the electrode array comprises 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, or 48, or more different electrodes. In certain embodiments the electrodes comprising the array are disposed in a substantially regular array pattern or an interlaced pattern, or an irregular pattern. In certain embodiments the electrodes comprising the array are spaced along a longitudinal axis by a distance ranging from about 0.2 mm up to about 15 mm, or from about 0.5 mm up to about 10 mm, or from about 0.5 mm up to about 6 mm, or from about 1 mm up to about 5 mm, or from about 2 mm up to about 4 mm, or by a distance of about 3 mm. In certain embodiments the contact surface(s) of electrodes comprising the array are substantially rectangular or substantially circular. In certain embodiments the contact surfaces of electrodes comprising the array are about 0.5 mm by 0.2 mm.
In various embodiments the polymer substrate comprises suture holes for fastening the array to a biological tissue. “In certain embodiments the substrate comprise 2, 3, 4, 5, or 6, or more suture holes.
In certain embodiments multiple electrode arrays are used to form an electrode array assembly. In certain embodiments the electrode array assembly comprises 2, 3, 4, 5, 6, 7, 8, or more electrode arrays. In certain embodiments the electrode arrays are physically coupled. In certain embodiments the electrode arrays are electrically coupled.
It will be recognized, that while the electrode arrays illustrated herein are shown a polymer substrate and second polymer layer of approximately the same thickness, in various embodiments the polymer substrate can be thicker or thinner than the second polymer layer.
It will also be noted that the electrodes may not need to have a fixed pitch size (distance of electrode center-to-center), but can vary in electrode placement.
It will also be noted that, in certain embodiments, the polymer substrate can also contain openings, e.g., to facilitate the attachment of leads (see, e.g.,
In certain embodiments the electrode array can be configured with pads that can be directly soldered with metal wires instead of using connectors.
Methods of fabricating the electrode arrays are described in Examples 1 and 2. In this regard, it is noted that among other steps, the methods involve roughening the polymer substrate before deposition of the electrode material, roughening the electrode contact area increase surface area and to improve double layer capacitance and therefore enhance the charge transfer capability, and optionally depositing a second polymer layer on top of the electrodes where the second polymer layer is provided with a plurality of openings. Without being bound to a particular theory it is believed the second polymer layer improves charge distribution around the electrode and improves the durability and mechanical stability of the electrode array.
The foregoing embodiments and the arrays shown in the Examples are intended to be illustrative and non-limiting. Using the teaching provided herein numerous other electrode arrays and electrode array assemblies having the improved durability and desirable electrical characteristics, e.g., as illustrated herein, will be available to one of skill in the art.
Uses of the Electrode Arrays.
The electrode arrays described herein find uses in a number of contexts. In general, the electrode arrays can be utilized in essentially any context where it is desired to deliver or receive an electrical stimulus, e.g., to a tissue. In certain embodiments the electrode arrays are particularly well suited for implantation into a subject, e.g., to directly stimulate muscle contractions (e.g., bladder contraction, eye blink, diaphragm contraction, etc.). However in certain embodiments, the electrode arrays are implanted into a subject to stimulate the spinal cord (or regions thereof) and thereby activate various central pattern generators and restore endogenous activation patters to stimulate or improve postural and/or locomotor activity and/or postural or locomotor strength, reaching, grasping, pushing, pulling, and/or to enabling one or more functions such as voluntary voiding of the bladder and/or bowel, sexual function, control of kidney function, cognitive function, autonomic control of cardiovascular function, breathing, chewing, swallowing, speaking, control of digestive function, control/regulation of body temperature control in a subject having a neurologically derived paralysis. The methods typically involve neuromodulating the spinal cord of the subject or a region thereof by administering epidural stimulation to the spinal cord or a region thereof using an electrical stimulator electrically coupled to an electrode array and/or an electrode array assembly described herein, where the electrode array or array assembly is implanted over the spinal cord or over one or more regions thereof, and/or overlaps a spinal nerve, nerve branch, nerve root.
Accordingly, in various embodiments methods and devices are provided to facilitate movement in a mammalian subject (e.g., a human) having spinal cord injury, brain injury, neurological disease or a physiological dysfunction. In certain embodiments the methods involve stimulating the spinal cord of the subject using an electrode array described herein where the stimulation modulates the electrophysiological properties of selected spinal circuits in the subject so they can be activated, e.g., by proprioceptive derived information and/or input from spinal and/or supraspinal nerves and nerve pathways. In various embodiments the stimulation can be accompanied by physical training (e.g., movement) of the region comprising sensory motor circuits involved in the desired motor activity. In certain embodiments, the epidural electrical stimulation is administered as described herein using parameters as described in PCT Publication Nos: WO/2012/094346 (PCT/US2012/020112).
In particular illustrative embodiments, the devices and methods described herein stimulate the spinal cord with one or more electrode arrays described herein, that modulate the proprioceptive and/or supraspinal information that controls the lower limbs during standing and/or stepping and/or the upper limbs during reaching and/or grasping conditions. This “sensory” information can guide the activation of the muscles in a coordinated manner and in a manner that accommodates the external conditions, e.g., the amount of loading, speed and direction of stepping or whether the load is equally dispersed on the two lower limbs, indicating a standing event, alternating loading indicating stepping, or sensing postural adjustments signifying the intent to reach and grasp.
Unlike approaches that involve specific stimulation of motor neurons to directly induce a movement, the methods described herein enable the spinal circuitry to control the movements. More specifically, the devices and methods described herein exploit the spinal circuitry and its ability to interpret proprioceptive and/or cutaneous information, and/or supraspinal information and/or autonomic information and to respond to that proprioceptive and/or cutaneous information in a functional way. In various embodiments this is in contrast to other approaches where the actual movement is induced/controlled by direct stimulation (e.g., of particular motor neurons and/or muscles).
In one illustrative embodiment, the subject is fitted with one or more implantable electrode arrays described herein that afford selective stimulation and control capability to select sites, mode(s), and intensity of stimulation via electrodes placed epidurally over, for example, the thoracic lumbar spinal cord and/or cervical spinal cord to facilitate movement of the arms and/or legs of individuals with a severely debilitating neuromotor disorder.
In certain embodiments the subject can receive the implant (e.g., in a standard procedure when used for pain alleviation) and typically about two weeks post implant the subject can be tested to identify the most effective subject specific stimulation paradigms for facilitation of movement (e.g., stepping and standing and/or arm and/or hand movement). In certain embodiments, using these stimulation paradigms the subject can practices standing and stepping and/or reaching or grabbing in an interactive rehabilitation program while being subject to spinal stimulation.
Depending on the site/type of injury and the locomotor or functional activity it is desired to facilitate particular spinal stimulation protocols include, but are not limited to specific stimulation sites along the lumbosacral and/or thoracic, cervical spinal cord and/or brainstem; specific combinations of stimulation sites along the lumbosacral and/or thoracic, cervical spinal cord, and/or brainstem; specific stimulation amplitudes; specific stimulation polarities (e.g., monopolar and bipolar stimulation modalities); specific stimulation frequencies; and/or specific stimulation pulse widths.
Epidural Stimulation of a Region of the Cervical Spine
In various embodiments, the methods described herein involve epidural electrical stimulation of the cervical spinal cord or a region of the cervical spinal cord of the subject utilizing one or more of the electrode arrays described herein. Illustrative regions include, but are not limited to, one or more regions straddling or spanning a region selected from the group consisting of C0-C1, C0-C2, C0-C3, C0-C4, C0-05, C0-C6, C0-C7, C1-C1, C1-C2, C1-C3, C1-C4, C1-C7, C1-C6, C1-C7, C1-T1, C2-C2, C2-C3, C2-C4, C2-05, C2-C6, C2-C7, C2-T1, C3-C3, C3-C4, C3-05, C3-C6, C3-C7, C3-T1, C4-C4, C4-05, C4-C6, C4-C7, C4-T1, C5-05, C5-C6, C5-C7, C5-T1, C6-C6, C6-C7, C6-T1, C7-C7, and C7-T1.
Epidural Stimulation of a Region of the Thoracic Spine
In various embodiments, the methods described herein involve epidural electrical stimulation of the thoracic spinal cord or a region of the thoracic spinal cord of the subject utilizing one or more of the electrode arrays described herein. Illustrative regions include, but are not limited to, one or more regions straddling or spanning a region selected from the group consisting of T1-T1, T1-T2, T1-T3, T1-T4, T1-T5, T1-T6, T1-T7, T1-T8, T1-T9, T1-T10, T1-T11, T1-T12, T2-T1, T2-T2, T2-T3, T2-T4, T2-T5, T2-T6, T2-T7, T2-T8, T2-T9, T2-T10, T2-T11, T2-T12, T3-T1, T3-T2, T3-T3, T3-T4, T3-T5, T3-T6, T3-T7, T3-T8, T3-T9, T3-T10, T3-T11, T3-T12, T4-T1, T4-T2, T4-T3, T4-T4, T4-T5, T4-T6, T4-T7, T4-T8, T4-T9, T4-T10, T4-T11, T4-T12, T5-T1, T5-T2, T5-T3, T5-T4, T5-T5, T5-T6, T5-T7, T5-T8, T5-T9, T5-T10, T5-T11, T5-T12, T6-T1, T6-T2, T6-T3, T6-T4, T6-T5, T6-T6, T6-T7, T6-T8, T6-T9, T6-T10, T6-T11, T6-T12, T7-T1, T7-T2, T7-T3, T7-T4, T7-T5, T7-T6, T7-T7, T7-T8, T7-T9, T7-T10, T7-T11, T7-T12, T8-T1, T8-T2, T8-T3, T8-T4, T8-T5, T8-T6, T8-T7, T8-T8, T8-T9, T8-T10, T8-T11, T8-T12, T9-T1, T9-T2, T9-T3, T9-T4, T9-T5, T9-T6, T9-T7, T9-T8, T9-T9, T9-T10, T9-T11, T9-T12, T10-T1, T10-T2, T10-T3, T10-T4, T10-T5, T10-T6, T10-T7, T10-T8, T10-T9, T10-T10, T10-T11, T10-T12, T11-T1, T11-T2, T11-T3, T11-T4, T11-T5, T11-T6, T11-T7, T11-T8, T11-T9, T11-T10, T11-T11, T11-T12, T12-T1, T12-T2, T12-T3, T12-T4, T12-T5, T12-T6, T12-T7, T12-T8, T12-T9, T12-T10, T12-T11, T12-T12, and T12-L1.
Epidural Stimulation of the Lumbosacral Spinal Cord.
In various embodiments, the methods described herein involve epidural electrical stimulation of the lumbosacral spinal cord or a region of the lumbosacral spinal cord of the subject utilizing one or more of the electrode arrays described herein. Illustrative regions include, but are not limited to, one or more regions straddling or spanning a region selected from the group consisting of L1-L1, L1-L2, L1-L3, L1-L4, L1-L5, L1-S1, L1-S2, L1-S3, L1-S4, L1-S5, L2-L2, L2-L3, L2-L4, L2-L5, L2-S1, L2-S2, L2-S3, L2-S4, L2-S5, L3-L3, L3-L4, L3-L5, L3-S1, L3-S2, L3-S3, L3-S4, L3-S5, L4-L4, L4-L5, L4-S1, L4-S2, L4-S3, L4-S4, L4-S5, L5-L5, L5-S1, L5-S2, L5-S3, L5-S4, L5-S5, S1-S1, S1-S2, S1-S3, S1-S4, S1-S5, S2-S2, S2-S3, S2-S4, S2-S5, S3-S3, S3-S4, S3-S5, S4-S4, and S4-S5.
Epidural Stimulation Parameters.
In certain embodiments, the epidural stimulation is at a frequency ranging from about 0.1 Hz or from about 0.5 Hz, or from about 1 Hz, or from about 2 Hz, or from about 3 Hz, or from about 5 Hz, or from about 10 Hz up to about 100 Hz, or up to about 80 Hz, or up to about 40 Hz, or from about 0.1 Hz up to about 100 Hz, or from about 1 Hz, or from about 3 Hz or from about 5 Hz up to about 80 Hz, or from about 5 Hz to about 30 Hz, or to about 40 Hz, or to about 50 Hz.
In certain embodiments, the epidural stimulation is at an amplitude ranging from 0.05 mA to about 30 mA, or from about 0.1 mA to about 20 mA, or from about 0.1 mA to about 15 mA or to about 10 mA.
In certain embodiments, the pulse width ranges from about 50 μs to 100 or 150 μs to about 600 μs, or to about 1000 μs or from about 200 μs to about 500 μs, or from about 200 μs to about 450 μs.
In certain embodiments the epidural stimulation is at a frequency and amplitude sufficient to stimulate or to improve postural and/or locomotor activity and/or postural or locomotor strength.
In certain embodiments the epidural stimulation is at a frequency and amplitude sufficient to stimulate or to improve upper extremity motion, and/or hand motion, and/or gripping, and/or grasping, and/or reaching, and/or pulling, and/or pushing.
In certain embodiments the epidural stimulation is at a frequency and amplitude sufficient to stimulate or improve autonomic function.
In certain embodiments the epidural stimulation is at a frequency and amplitude sufficient to stimulate or improve voluntary voiding of the bladder and/or bowel, and/or return of sexual function, and/or autonomic control of cardiovascular function, and/or body temperature.
In certain embodiments the epidural stimulation is at a frequency and amplitude sufficient to stimulate or improve ventilation, and/or swallowing, and/or chewing, and/or speaking, and/or cognitive function.
In certain embodiments, the epidural stimulation is at a frequency and amplitude sufficient to improve hand strength and/or fine hand control. In certain embodiments the epidural stimulation is applied paraspinally over a cervical region identified above (e.g., over vertebrae spanning C2 to T1, over vertebrae spanning C5 to T1, etc.).
In certain embodiments, the epidural stimulation is applied paraspinally over a thoracic region identified above (e.g., over vertebrae spanning T11-T12).
In certain embodiments, the epidural stimulation is applied via a one or more electrode arrays described herein that have been surgically “permanently” implanted.
In certain embodiments, the epidural electrical stimulation is administered to an electrode array described herein using parameters as described in PCT Publication Nos: WO/2012/094346 (PCT/US2012/020112), and WO/2015/048563 (PCT/US2014/057886).
In certain embodiments the epidural stimulation is at a frequency and amplitude sufficient to stimulating or improving postural and/or locomotor activity and/or postural or locomotor strength, and/or reaching, grasping, pushing, pulling,
In certain embodiments the epidural stimulation is at a frequency and amplitude sufficient to stimulate or facilitate voluntary voiding of the bladder and/or bowel, and/or return of sexual function, control of kidney function, cognitive function, and/or autonomic control of cardiovascular function, or breathing, chewing, swallowing, speaking, control of digestive function, and/or control/regulation of body temperature.
In certain embodiments the epidural stimulation is at a frequency and amplitude sufficient to improve hand strength and/or fine hand control. With respect to hand control, it is noted that WO/2015/048563 (PCT/US2014/057886) shows that the cervical spinal cord can be neuromodulated using two paradigms, i.e., electrically and pharmacologically. Moreover, the data presented therein indicate that non-functional networks can become engaged and progressively improve motor performance. In addition, the further improvement in hand function after withdrawing painless cutaneous Enabling motor control (pcEmc) and pharmacological Enabling motor control (fEmc) suggests that once functional connections are established they remain active. The methods described in WO/2015/048563 can be further enhanced by the use of the improved electrode arrays described herein when part of a system comprising a pulse generator such as that described in PCT US2012/030624, and the like.
Similarly WO/2012/094346 demonstrates that locomotor activity and/or strength and/or posture can be improved and/or restored by stimulation of the spinal circuitry. The methods described in WO/2012/094346 can be further enhanced by the use of the improved electrode arrays described herein.
As noted above, the electrode array may be implanted using any of a number of methods (e.g., a laminectomy procedure) well known to those of skill in the art.
In various embodiments, the arrays are operably linked to control circuitry that permits selection of electrode(s) or groups of electrodes to activate/stimulate and/or that controls frequency, and/or pulse width, and/or amplitude of stimulation. In various embodiments, the electrode selection, frequency, amplitude, and pulse width are independently selectable, e.g., at different times, different electrodes or groups of electrodes can be selected. At any time, different electrodes or groups of electrodes can provide different stimulation frequencies and/or amplitudes. In various embodiments, different electrodes or all electrodes can be operated in a monopolar mode and/or a bipolar mode, monophasic and/or biphasic using constant current or constant voltage delivery of the stimulation.
In certain embodiments, the electrodes can also be provided with implantable control circuitry and/or an implantable power source. In various embodiments, the implantable control circuitry can be programmed/reprogrammed by use of an external device (e.g., using a handheld device that communicates with the control circuitry through the skin). The programming can be repeated as often as necessary.
Any present or future developed stimulation system capable of providing an electrical signal to one or more regions of the cervical spinal cord using the electrode array(s) described herein may be used in accordance with the teachings provided herein. In various embodiments, the system may comprise an external pulse generator. In other embodiments the system may comprise an implantable pulse generator to produce a number of stimulation pulses that are sent to the a region in proximity to the cervical thoracic, lumbar, or lumbarsacral spinal cord by insulated leads coupled to the spinal cord by one or more electrodes and/or an electrode array. In certain embodiments the one or more electrodes or one or more electrodes comprising the electrode array may be attached to separate conductors included within a single lead.
Any external or implantable pulse generator may be used in accordance with the teachings provided herein. For example, one internal pulse generator may be an ITREL® II or Synergy or Restore Advanced pulse generator available from Medtronic, Inc, Advanced Neuromodulation Systems, Inc.'s GENESIS™ pulse generator, or Boston Scientific's Corporation's PRECISION™ pulse generator. One of skill in the art will recognize that the above-mentioned pulse generators may be advantageously modified to deliver therapy in accordance with the teachings provided herein.
In certain embodiments systems can employ a programmer coupled via a conductor to a radio frequency antenna. This system permits attending medical personnel to select the various pulse output options after implant using radio frequency communications. While, in certain embodiments, the system employs fully implanted elements, systems employing partially implanted elements may also be used in accordance with the teachings provided herein.
In one illustrative, but non-limiting system, a control module is operably coupled to a signal generation module and instructs the signal generation module regarding the signal to be generated. For example, at any given time or period of time, the control module may instruct the signal generation module to generate an electrical signal having a specified pulse width, frequency, intensity (current or voltage), etc. The control module may be preprogrammed prior to implantation or receive instructions from a programmer (or another source) through any known or future developed mechanism, such as telemetry. The control module may include or be operably coupled to memory to store instructions for controlling the signal generation module and may contain a processor for controlling which instructions to send to signal generation module and the timing of the instructions to be sent to signal generation module. In various embodiments, leads are operably coupled to signal generation module such that a stimulation pulse generated by signal generation module may be delivered via electrodes.
While in certain embodiments, two leads are utilized, it will be understood that any number of one or more leads may be employed. In addition, it will be understood that any number of one or more electrodes per lead may be employed. Stimulation pulses are applied to electrodes (which typically are cathodes) with respect to a return electrode (which typically is an anode) to induce a desired area of excitation of electrically excitable tissue in a region of the cervical spine. A return electrode such as a ground or other reference electrode and/or a recording electrode can be located on same lead as a stimulation electrode. However, it will be understood that a return electrode may be located at nearly any location, whether in proximity to the stimulation electrode or at a more remote part of the body, such as at a metallic case of a pulse generator. It will be further understood that any number of one or more return electrodes may be employed. For example, there can be a respective return electrode for each cathode such that a distinct cathode/anode pair is formed for each cathode.
The epidural electrode stimulation systems described herein are intended to be illustrative and non-limiting. Using the electrode arrays, fabrication methods, and teachings provided herein, alternative epidural stimulation systems and methods will be available to one of skill in the art.
Use of Neuromodulatory Agents.
In certain embodiments, the transcutaneous and/or epidural stimulation methods described herein are used in conjunction with various pharmacological agents, particularly pharmacological agents that have neuromodulatory activity (e.g., that are monoamergic). In certain embodiments, the use of various serotonergic, and/or dopaminergic, and/or noradrenergic, and/or GABAergic, and/or glycinergic drugs is contemplated. These agents can be used in conjunction with epidural stimulation and/or transcutaneous stimulation and/or physical therapy as described above. This combined approach can help to put the spinal cord (e.g., the cervical spinal cord) in an optimal physiological state for controlling a range of hand and/or upper limb movements.
In certain embodiments, the drugs are administered systemically, while in other embodiments, the drugs are administered locally, e.g., to particular regions of the spinal cord. Drugs that modulate the excitability of the spinal neuromotor networks include, but are not limited to combinations of noradrenergic, serotonergic, GABAergic, and glycinergic receptor agonists and antagonists.
Dosages of at least one drug or agent can be between about 0.001 mg/kg and about 10 mg/kg, between about 0.01 mg/kg and about 10 mg/kg, between about 0.01 mg/kg and about 1 mg/kg, between about 0.1 mg/kg and about 10 mg/kg, between about 5 mg/kg and about 10 mg/kg, between about 0.01 mg/kg and about 5 mg/kg, between about 0.001 mg/kg and about 5 mg/kg, or between about 0.05 mg/kg and about 10 mg/kg. Typically where the drug is an approved drug, it will be administered at dosage consistent with the recommended/approved dosage for that drug.
Drugs or agents can be delivery by injection (e.g., subcutaneously, intravenously, intramuscularly), orally, rectally, or inhaled.
Illustrative pharmacological agents include, but are not limited to, agonists and antagonists to one or more combinations of serotonergic: 5-HT1A, 5-HT2A, 5-HT3, and 5HT7 receptors; to noradrenergic alpha 1 and 2 receptors; and to dopaminergic D1 and D2 receptors (see, e.g., Table 1).
The foregoing methods are intended to be illustrative and non-limiting. Using the teachings provided herein, other methods involving epidural electrical stimulation and/or the use of neuromodulatory agents to stimulate or improve postural and/or locomotor, motor activity and/or postural or locomotor, or motor strength and/or to enabling one or more functions such as voluntary voiding of the bladder and/or bowel, sexual function, autonomic control of cardiovascular function, control/regulation of body temperature control, kidney control, control of digestion, improvement in cognitive function, and the like in a subject having a neurologically derived paralysis.
The following examples are offered to illustrate, but not to limit the claimed invention.
A detailed design, fabrication, characterization and test of a flexible multi-site platinum/polyimide based electrode array for electrical epidural stimulation in spinal cord prosthesis is described in this example. Carefully designed 8.4 μm-thick structure fabrication flow achieved an electrode surface modification with 3.8 times enhanced effective surface area without extra process needed. Measured impedance and phase of two type of electrodes are 2.35±0.21 KΩ and 2.10±0.11 KΩ, −34.25±8.07° and −27.71±8.27° at 1K Hz, respectively. The fabricated arrays were then in-vitro tested by a multichannel neural stimulation system in physiological saline to validate the capability for electrical stimulation. The measured channel isolation on adjacent electrode is about −34 dB. A Randles cell model was used to investigate the charging waveforms, the model parameters were then extracted by various methods. The measured charge transfer resistance, double layer capacitance, and solution resistance are 1.9 KΩ, 220 nF and 15 KΩ, respectively. The results show that the fabricated array is applicable for electrical stimulation with well characterized parameters. Combined with a multichannel stimulator, this system provides a full solution for versatile neural stimulation applications.
In this example, we describe a flexible multi-site polymer electrode array for epidural spinal cord stimulation. For the selection of the materials, several design features were taken into account. Low stress thin film polyimide was chosen as electrode substrate because of its superior high mechanical strength, low moisture uptake rate, low dielectric constant property with great biocompatibility than other polymers (Walewyns (2013) J. Micromechanics and Microengineering, 23(9): 095021). Platinum/Titanium metal layer was selected for its high stability and biocompatibility. A roughening process was used to increase the effective surface area. This in turn lowered the electrode-electrolyte interface impedance as well as the compliance working voltage to allow the induced electrode to be operated within the water window (Merrill et al. (2005) J. Neurosci. Meth. 141: 171-198). Electrode density was taken into consideration when designing the array. Dense arrays provide more stimulus pattern combinations, but similar or unwanted stimulus effect may happen in the neighborhood of the stimulated electrode due to limited stimulus spatial resolution between adjacent electrodes. In vitro stimulation test of the fabricated array was demonstrated by using a multichannel stimulator in saline solution. This work also presents an electrode-electrolyte modeling via a new time-domain large signal analysis method developed by our group (Yi-Kai Lo et al. (2014) “Bio-Impedance Acquisition Technique Using Biphasic Current Stimulus Excitation for Implantable Neural Stimulator,” Conf Proc IEEE Eng Med Biol Soc. August:474-477). Detailed design and characterization procedures and results are described in the following sections.
Electrode Design and Fabrication
Fabrication Results and Characterization
Stimulation Test by Multichannel Stimulation System
To validate the electrode performance in practical stimulation, the fabricated electrodes were tested using a multichannel current-mode neural stimulator (L. Yi-Kai, C. Kuanfu, P. Gad, and L. Wentai, (2013) Biomedical Circuits and Systems, IEEE Transactions on, 7(6): 761-772, 2013) developed by our group with the same physiological saline solution setup as the impedance analysis, as shown in
The stimulation result was displayed in
Coupling effect was evaluated by injecting stimulus current into an electrode, and recording the coupled stimulus signal from a nearest adjacent electrode. As shown in
To investigate the validity of the electrode model in detail, we used an impedance acquisition technique based on large signal analysis developed in our group (Yi-Kai Lo et al. (2014) Conf Proc IEEE Eng Med Biol Soc. August:474-477). The parameters of the Randles cell electrode model can be inferred from the pre-determined stimulus parameters, such as pulse width and interpulse delay, and measurement of the resulting transient electrode voltage. The RS can also be validated by looking into the impedance in very high frequency in
Zero=½πCdl(RCT∥RS) (1)
RCT might be able to be ignored if RCT>>RS. A summary of the specifications of the fabricated array are shown in Table 2.
A flexible polymer electrode array was designed, fabricated, characterized and in-vitro tested using a multichannel stimulator in saline solution for the demonstration of electrical spinal cord stimulation. Low stress polyimide with superior mechanical properties was used to meet the requirements of a good spinal cord implant. Various electrode grid window and array arrangements were proposed to enhance the uniformity of the stimulus charge density and the stimulation pattern combinations. The roughened platinum electrode surface yielded a 3.8× effective area which increased the equivalent double layer capacitance and therefore enhanced the charge transfer capability. The electrode transient waveform was investigated using a lumped Randles cell model with a multichannel stimulation system, which allowed examination of the channel isolation and extraction of the parameters of the electrode model. The model was further validated by various approaches including the large signal analysis technique, AFM and impedance analyzer. The results show that the fabricated electrode is applicable for electrical stimulation with well characterized performance. Combined with a multichannel stimulator, this array completes a full system solution for various applications.
The following protocol was used to fabricate the multi-electrode array shown in
A) Chromium/Aluminum (200 nm/500 nm) layer was deposited by E-beam evaporated deposition (CHA Mark 40) on to a handle silicon wafer.
B) Adhesion promoter (VM-651, HD Microsystems) was applied onto the Chromium/Aluminum layer to create a Si—C bond and provide additional adhesion for the first polyimide layer.
C) A 4.2 μm polyimide (PI-2611, HD Microsystems) was spin-coated onto the wafer, and cured in 350° C. for 30 minutes in a nitrogen-controlled oven to form full cross-link in the polyimide.
D) Positive photoresister AZ4620 was spin-coated onto the wafer. Create the metal pattern by microphotolithography.
E) An oxygen-plasma roughening process was applied to the polyimide layer for 30 seconds to enhance the adhesion performance.
F) Titanium/Platinum (10 nm/200 nm) layer was defined and deposited using E-beam evaporated deposition (CHA Mark 40).
G) Use Lift-off to define the metal pattern from the photoresister.
H) Another 4.2 μm polyimide (PI-2611, HD Microsystems) was spin-coated onto the wafer, and cured in 350° C. for 30 minutes in a nitrogen-controlled oven.
I) A silicon dioxide (200 nm) film was deposited using a DC sputter (Denton Discovery-550) and defined by CHF3/Ar reactive ion etch (RIE) process using a plasma etcher (Oxford Plasmalab-80 Plus).
J) Positive photoresister AZ4620 was spin-coated onto the wafer. Create the electrode pattern by microphotolithography.
K) A pure oxygen plasma process was used to define the array shape as well as exposing the metal layer of electrodes and connector pads.
L) An extra oxygen/CF4 RIE process was utilized to remove the residual layer composed of the silicon containing active ingredient (a-aminopropyltriethoxysilane) which is caused by the Si—C bond promoter. The fluorine etching on platinum in the oxygen/CF4 RIE process roughens the platinum surface.
M) Finally, the electrode arrays were detached from the handle wafer by anodic metal dissolution in a 10 wt % sodium chloride solution. The anodic metal dissolution process dissolved the aluminum, leaving the chrome on the substrate, thus releasing the polyimide electrode arrays.
N) Neural Connector (Omnetics) was soldered onto the arrays. Silicone encapsulation (Sylgard 184) was then applied to seal all the soldering parts and cured in a 120° C. oven for 20 minutes to fully coagulate.
A fluorine added oxygen/CF4 plasma RIE process in step (L) was designed to accomplish two goals in one step: (1) removal of the residual silicon composite from the adhesion promoter Si—C bond; and (2) Roughening the platinum surface by fluorine attack.
It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and scope of the appended claims. All publications, patents, and patent applications cited herein are hereby incorporated by reference in their entirety for all purposes.
This application is a U.S. 371 National Phase of PCT/US2015/047268, filed Aug. 27, 2015, which claims benefit of and priority to U.S. Ser. No. 62/042,672, filed on Aug. 27, 2014, and to U.S. Ser. No. 62/171,427, filed on Jun. 5, 2015, all of which are incorporated herein by reference in their entirety for all purposes.
This invention was made with Government support under EB007615 and NS062009, awarded by the National Institutes of Health. The Government has certain rights in the invention.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/US2015/047268 | 8/27/2015 | WO | 00 |
| Publishing Document | Publishing Date | Country | Kind |
|---|---|---|---|
| WO2016/033369 | 3/3/2016 | WO | A |
| Number | Name | Date | Kind |
|---|---|---|---|
| 3543761 | Bradley | Dec 1970 | A |
| 3662758 | Glover | May 1972 | A |
| 3724467 | Avery et al. | Apr 1973 | A |
| 4044774 | Corbin et al. | Aug 1977 | A |
| 4102344 | Conway et al. | Jul 1978 | A |
| 4141365 | Fischell et al. | Feb 1979 | A |
| 4285347 | Hess | Aug 1981 | A |
| 4340063 | Maurer | Jul 1982 | A |
| 4379462 | Borkan et al. | Apr 1983 | A |
| 4414986 | Dickhudt et al. | Nov 1983 | A |
| 4538624 | Tarjan | Sep 1985 | A |
| 4549556 | Tajan et al. | Oct 1985 | A |
| 4559948 | Liss et al. | Dec 1985 | A |
| 4573481 | Bullara et al. | Mar 1986 | A |
| 4800898 | Hess et al. | Jan 1989 | A |
| 4934368 | Lynch | Jun 1990 | A |
| 4969452 | Petrofsky et al. | Nov 1990 | A |
| 5002053 | Garcia-Rill et al. | Mar 1991 | A |
| 5031618 | Mullett | Jul 1991 | A |
| 5066272 | Eaton et al. | Nov 1991 | A |
| 5081989 | Graupe et al. | Jan 1992 | A |
| 5121754 | Mullett | Jun 1992 | A |
| 5344439 | Otten | Sep 1994 | A |
| 5354320 | Schaldach et al. | Oct 1994 | A |
| 5374285 | Vaiani et al. | Dec 1994 | A |
| 5417719 | Hull et al. | May 1995 | A |
| 5476441 | Durfee et al. | Dec 1995 | A |
| 5562718 | Palermo | Oct 1996 | A |
| 5643330 | Holsheimer et al. | Jul 1997 | A |
| 5733322 | Starkebaum | Mar 1998 | A |
| 5983141 | Sluijter et al. | Nov 1999 | A |
| 6066163 | John | May 2000 | A |
| 6104957 | Alo et al. | Aug 2000 | A |
| 6122548 | Starkebaum et al. | Sep 2000 | A |
| 6308103 | Gielen | Oct 2001 | B1 |
| 6319241 | King et al. | Nov 2001 | B1 |
| 6470213 | Alley | Oct 2002 | B1 |
| 6500110 | Davey et al. | Dec 2002 | B1 |
| 6503231 | Prausnitz et al. | Jan 2003 | B1 |
| 6505074 | Boveja et al. | Jan 2003 | B2 |
| 6551849 | Kenney | Apr 2003 | B1 |
| 6587724 | Mann | Jul 2003 | B2 |
| 6662053 | Borkan | Dec 2003 | B2 |
| 6666831 | Edgerton et al. | Dec 2003 | B1 |
| 6685729 | Gonzalez | Feb 2004 | B2 |
| 6819956 | DiLorenzo | Nov 2004 | B2 |
| 6839594 | Cohen et al. | Jan 2005 | B2 |
| 6871099 | Whitehurst et al. | Mar 2005 | B1 |
| 6892098 | Ayal et al. | May 2005 | B2 |
| 6895280 | Meadows et al. | May 2005 | B2 |
| 6895283 | Erickson et al. | May 2005 | B2 |
| 6937891 | Leinders et al. | Aug 2005 | B2 |
| 6950706 | Rodriguez et al. | Sep 2005 | B2 |
| 6975907 | Zanakis et al. | Dec 2005 | B2 |
| 6988006 | King et al. | Jan 2006 | B2 |
| 6999820 | Jordan | Feb 2006 | B2 |
| 7020521 | Brewer et al. | Mar 2006 | B1 |
| 7024247 | Gliner et al. | Apr 2006 | B2 |
| 7035690 | Goetz | Apr 2006 | B2 |
| 7047084 | Erickson et al. | May 2006 | B2 |
| 7065408 | Herman et al. | Jun 2006 | B2 |
| 7096070 | Jenkins et al. | Aug 2006 | B1 |
| 7110820 | Tcheng et al. | Sep 2006 | B2 |
| 7127287 | Duncan et al. | Oct 2006 | B2 |
| 7127296 | Bradley | Oct 2006 | B2 |
| 7127297 | Law et al. | Oct 2006 | B2 |
| 7153242 | Goffer | Dec 2006 | B2 |
| 7184837 | Goetz | Feb 2007 | B2 |
| 7200443 | Faul | Apr 2007 | B2 |
| 7209787 | DiLorenzo | Apr 2007 | B2 |
| 7228179 | Campen et al. | Jun 2007 | B2 |
| 7239920 | Thacker et al. | Jul 2007 | B1 |
| 7251529 | Greenwood-Van Meerveld | Jul 2007 | B2 |
| 7252090 | Goetz | Aug 2007 | B2 |
| 7313440 | Miesel et al. | Dec 2007 | B2 |
| 7324853 | Ayal et al. | Jan 2008 | B2 |
| 7330760 | Heruth et al. | Feb 2008 | B2 |
| 7337005 | Kim et al. | Feb 2008 | B2 |
| 7337006 | Kim et al. | Feb 2008 | B2 |
| 7381192 | Brodard et al. | Jun 2008 | B2 |
| 7415309 | McIntyre | Aug 2008 | B2 |
| 7463928 | Lee et al. | Dec 2008 | B2 |
| 7467016 | Colborn | Dec 2008 | B2 |
| 7493170 | Segel et al. | Feb 2009 | B1 |
| 7496404 | Meadows et al. | Feb 2009 | B2 |
| 7502652 | Gaunt et al. | Mar 2009 | B2 |
| 7536226 | Williams et al. | May 2009 | B2 |
| 7544185 | Bengtsson | Jun 2009 | B2 |
| 7584000 | Erickson | Sep 2009 | B2 |
| 7590454 | Garabedian et al. | Sep 2009 | B2 |
| 7603178 | North et al. | Oct 2009 | B2 |
| 7628750 | Cohen et al. | Dec 2009 | B2 |
| 7660636 | Castel et al. | Feb 2010 | B2 |
| 7697995 | Cross et al. | Apr 2010 | B2 |
| 7729781 | Swoyer et al. | Jun 2010 | B2 |
| 7734340 | De Ridder | Jun 2010 | B2 |
| 7734351 | Testerman et al. | Jun 2010 | B2 |
| 7769463 | Katsnelson | Aug 2010 | B2 |
| 7797057 | Harris | Sep 2010 | B2 |
| 7801601 | Maschino et al. | Sep 2010 | B2 |
| 7813803 | Heruth et al. | Oct 2010 | B2 |
| 7813809 | Strother et al. | Oct 2010 | B2 |
| 7856264 | Firlik et al. | Dec 2010 | B2 |
| 7877146 | Rezai et al. | Jan 2011 | B2 |
| 7890182 | Parramon et al. | Feb 2011 | B2 |
| 7949395 | Kuzma | May 2011 | B2 |
| 7949403 | Palermo et al. | May 2011 | B2 |
| 7987000 | Moffitt et al. | Jul 2011 | B2 |
| 7991465 | Bartic et al. | Aug 2011 | B2 |
| 8019427 | Moffitt | Sep 2011 | B2 |
| 8050773 | Zhu | Nov 2011 | B2 |
| 8108052 | Boling | Jan 2012 | B2 |
| 8131358 | Moffitt et al. | Mar 2012 | B2 |
| 8155750 | Jaax et al. | Apr 2012 | B2 |
| 8170660 | Dacey, Jr. et al. | May 2012 | B2 |
| 8190262 | Gerber et al. | May 2012 | B2 |
| 8195304 | Strother et al. | Jun 2012 | B2 |
| 8214048 | Whitehurst et al. | Jul 2012 | B1 |
| 8229565 | Kim et al. | Jul 2012 | B2 |
| 8239038 | Wolf, II | Aug 2012 | B2 |
| 8260436 | Gerber et al. | Sep 2012 | B2 |
| 8271099 | Swanson | Sep 2012 | B1 |
| 8295936 | Wahlstrand et al. | Oct 2012 | B2 |
| 8311644 | Moffitt et al. | Nov 2012 | B2 |
| 8332029 | Glukhovsky et al. | Dec 2012 | B2 |
| 8346366 | Arle et al. | Jan 2013 | B2 |
| 8352036 | DiMarco et al. | Jan 2013 | B2 |
| 8355791 | Moffitt | Jan 2013 | B2 |
| 8355797 | Caparso et al. | Jan 2013 | B2 |
| 8364273 | De Ridder | Jan 2013 | B2 |
| 8369961 | Christman et al. | Feb 2013 | B2 |
| 8412345 | Moffitt | Apr 2013 | B2 |
| 8428728 | Sachs | Apr 2013 | B2 |
| 8442655 | Moffitt et al. | May 2013 | B2 |
| 8452406 | Arcot-Krishmamurthy et al. | May 2013 | B2 |
| 8588884 | Hegde et al. | Nov 2013 | B2 |
| 8700145 | Kilgard et al. | Apr 2014 | B2 |
| 8712546 | Kim et al. | Apr 2014 | B2 |
| 8750957 | Tang et al. | Jun 2014 | B2 |
| 8805542 | Tai et al. | Aug 2014 | B2 |
| 9072891 | Rao | Jul 2015 | B1 |
| 9101769 | Edgerton et al. | Aug 2015 | B2 |
| 9205259 | Kim et al. | Dec 2015 | B2 |
| 9205260 | Kim et al. | Dec 2015 | B2 |
| 9205261 | Kim et al. | Dec 2015 | B2 |
| 9272143 | Libbus et al. | Mar 2016 | B2 |
| 9283391 | Ahmed | Mar 2016 | B2 |
| 9393409 | Edgerton et al. | Jul 2016 | B2 |
| 9415218 | Edgerton et al. | Aug 2016 | B2 |
| 9610442 | Yoo et al. | Apr 2017 | B2 |
| 9993642 | Gerasimenko et al. | Jun 2018 | B2 |
| 10137299 | Lu et al. | Nov 2018 | B2 |
| 20020055779 | Andrews | May 2002 | A1 |
| 20020111661 | Cross et al. | Aug 2002 | A1 |
| 20020115945 | Herman et al. | Aug 2002 | A1 |
| 20020193843 | Hill et al. | Dec 2002 | A1 |
| 20030032992 | Thacker et al. | Feb 2003 | A1 |
| 20030078633 | Firlik et al. | Apr 2003 | A1 |
| 20030100933 | Ayal et al. | May 2003 | A1 |
| 20030158583 | Burnett et al. | Aug 2003 | A1 |
| 20030208248 | Carter et al. | Nov 2003 | A1 |
| 20030220679 | Han | Nov 2003 | A1 |
| 20030233137 | Paul, Jr. | Dec 2003 | A1 |
| 20040039425 | Greenwood-Van Meerveld | Feb 2004 | A1 |
| 20040044380 | Bruninga et al. | Mar 2004 | A1 |
| 20040111118 | Hill et al. | Jun 2004 | A1 |
| 20040111126 | Tanagho et al. | Jun 2004 | A1 |
| 20040122483 | Nathan et al. | Jun 2004 | A1 |
| 20040127954 | McDonald et al. | Jul 2004 | A1 |
| 20040133248 | Frei et al. | Jul 2004 | A1 |
| 20040138518 | Rise et al. | Jul 2004 | A1 |
| 20050004622 | Cullen et al. | Jan 2005 | A1 |
| 20050043775 | John et al. | Feb 2005 | A1 |
| 20050070982 | Heruth et al. | Mar 2005 | A1 |
| 20050075669 | King | Apr 2005 | A1 |
| 20050075678 | Faul | Apr 2005 | A1 |
| 20050102007 | Ayal et al. | May 2005 | A1 |
| 20050113882 | Cameron et al. | May 2005 | A1 |
| 20050119713 | Whitehurst et al. | Jun 2005 | A1 |
| 20050125045 | Brighton et al. | Jun 2005 | A1 |
| 20050203588 | King | Sep 2005 | A1 |
| 20050209655 | Bradley et al. | Sep 2005 | A1 |
| 20050246004 | Cameron et al. | Nov 2005 | A1 |
| 20050278000 | Strother et al. | Dec 2005 | A1 |
| 20060003090 | Rodger et al. | Jan 2006 | A1 |
| 20060041295 | Osypka | Feb 2006 | A1 |
| 20060089696 | Olsen et al. | Apr 2006 | A1 |
| 20060100671 | Ridder | May 2006 | A1 |
| 20060111754 | Rezai et al. | May 2006 | A1 |
| 20060122678 | Olsen et al. | Jun 2006 | A1 |
| 20060142816 | Fruitman et al. | Jun 2006 | A1 |
| 20060142822 | Tulgar | Jun 2006 | A1 |
| 20060149333 | Tanagho et al. | Jul 2006 | A1 |
| 20060149337 | John | Jul 2006 | A1 |
| 20060239482 | Hatoum | Oct 2006 | A1 |
| 20070016097 | Farquhar et al. | Jan 2007 | A1 |
| 20070016266 | Paul, Jr. | Jan 2007 | A1 |
| 20070016268 | Carter et al. | Jan 2007 | A1 |
| 20070049814 | Muccio | Mar 2007 | A1 |
| 20070055337 | Tanrisever | Mar 2007 | A1 |
| 20070060954 | Cameron et al. | Mar 2007 | A1 |
| 20070060980 | Strother et al. | Mar 2007 | A1 |
| 20070073357 | Rooney et al. | Mar 2007 | A1 |
| 20070083240 | Peterson et al. | Apr 2007 | A1 |
| 20070156179 | S.E. | Jul 2007 | A1 |
| 20070168008 | Olsen | Jul 2007 | A1 |
| 20070179534 | Firlik et al. | Aug 2007 | A1 |
| 20070191709 | Swanson | Aug 2007 | A1 |
| 20070208381 | Hill et al. | Sep 2007 | A1 |
| 20070233204 | Lima et al. | Oct 2007 | A1 |
| 20070255372 | Metzler et al. | Nov 2007 | A1 |
| 20070265679 | Bradley et al. | Nov 2007 | A1 |
| 20070265691 | Swanson | Nov 2007 | A1 |
| 20070276449 | Gunter et al. | Nov 2007 | A1 |
| 20070276450 | Meadows et al. | Nov 2007 | A1 |
| 20080021513 | Thacker et al. | Jan 2008 | A1 |
| 20080046049 | Skubitz et al. | Feb 2008 | A1 |
| 20080051851 | Lin | Feb 2008 | A1 |
| 20080071325 | Bradley | Mar 2008 | A1 |
| 20080103579 | Gerber | May 2008 | A1 |
| 20080140152 | Imran et al. | Jun 2008 | A1 |
| 20080140169 | Imran | Jun 2008 | A1 |
| 20080147143 | Popovic et al. | Jun 2008 | A1 |
| 20080154329 | Pyles et al. | Jun 2008 | A1 |
| 20080183224 | Barolat | Jul 2008 | A1 |
| 20080200749 | Zheng et al. | Aug 2008 | A1 |
| 20080202940 | Jiang et al. | Aug 2008 | A1 |
| 20080207985 | Farone | Aug 2008 | A1 |
| 20080215113 | Pawlowicz | Sep 2008 | A1 |
| 20080221653 | Agrawal et al. | Sep 2008 | A1 |
| 20080228241 | Sachs | Sep 2008 | A1 |
| 20080228250 | Mironer | Sep 2008 | A1 |
| 20080234791 | Arle et al. | Sep 2008 | A1 |
| 20080255582 | Harris | Oct 2008 | A1 |
| 20080279896 | Heinen et al. | Nov 2008 | A1 |
| 20090005844 | Swoyer et al. | Jan 2009 | A1 |
| 20090012436 | Lanfermann et al. | Jan 2009 | A1 |
| 20090093854 | Leung et al. | Apr 2009 | A1 |
| 20090112281 | Miyazawa et al. | Apr 2009 | A1 |
| 20090118365 | Benson, III et al. | May 2009 | A1 |
| 20090157141 | Chiao et al. | Jun 2009 | A1 |
| 20090198305 | Naroditsky et al. | Aug 2009 | A1 |
| 20090204173 | Fang et al. | Aug 2009 | A1 |
| 20090270960 | Zhao et al. | Oct 2009 | A1 |
| 20090281599 | Thacker et al. | Nov 2009 | A1 |
| 20090299166 | Nishida et al. | Dec 2009 | A1 |
| 20090299167 | Seymour | Dec 2009 | A1 |
| 20090306491 | Haggers | Dec 2009 | A1 |
| 20100004715 | Fahey | Jan 2010 | A1 |
| 20100023069 | Moffitt et al. | Jan 2010 | A1 |
| 20100023070 | Moffitt et al. | Jan 2010 | A1 |
| 20100023103 | Elborno | Jan 2010 | A1 |
| 20100042193 | Slavin | Feb 2010 | A1 |
| 20100063568 | Staunton et al. | Mar 2010 | A1 |
| 20100070007 | Parker et al. | Mar 2010 | A1 |
| 20100114239 | McDonald et al. | May 2010 | A1 |
| 20100125313 | Lee et al. | May 2010 | A1 |
| 20100137938 | Kishawi et al. | Jun 2010 | A1 |
| 20100145428 | Cameron et al. | Jun 2010 | A1 |
| 20100152811 | Flaherty | Jun 2010 | A1 |
| 20100185253 | Dimarco et al. | Jul 2010 | A1 |
| 20100198298 | Glukhovsky et al. | Aug 2010 | A1 |
| 20100217355 | Tass et al. | Aug 2010 | A1 |
| 20100228310 | Shuros et al. | Sep 2010 | A1 |
| 20100241191 | Testerman et al. | Sep 2010 | A1 |
| 20100268299 | Farone | Oct 2010 | A1 |
| 20100274312 | Alataris et al. | Oct 2010 | A1 |
| 20100305660 | Hegi et al. | Dec 2010 | A1 |
| 20100318168 | Bighetti | Dec 2010 | A1 |
| 20100331925 | Peterson | Dec 2010 | A1 |
| 20110029040 | Walker et al. | Feb 2011 | A1 |
| 20110040349 | Graupe | Feb 2011 | A1 |
| 20110054567 | Lane et al. | Mar 2011 | A1 |
| 20110054568 | Lane et al. | Mar 2011 | A1 |
| 20110054579 | Kumar et al. | Mar 2011 | A1 |
| 20110118815 | Kuzma et al. | May 2011 | A1 |
| 20110125203 | Simon et al. | May 2011 | A1 |
| 20110130804 | Lin et al. | Jun 2011 | A1 |
| 20110152967 | Simon et al. | Jun 2011 | A1 |
| 20110160810 | Griffith | Jun 2011 | A1 |
| 20110166546 | Jaax et al. | Jul 2011 | A1 |
| 20110184488 | De Ridder | Jul 2011 | A1 |
| 20110184489 | Nicolelis et al. | Jul 2011 | A1 |
| 20110218594 | Doran et al. | Sep 2011 | A1 |
| 20110224665 | Crosby et al. | Sep 2011 | A1 |
| 20110224752 | Rolston et al. | Sep 2011 | A1 |
| 20110224753 | Palermo et al. | Sep 2011 | A1 |
| 20110224757 | Zdeblick et al. | Sep 2011 | A1 |
| 20110230701 | Simon et al. | Sep 2011 | A1 |
| 20110245734 | Wagner et al. | Oct 2011 | A1 |
| 20110276107 | Simon et al. | Nov 2011 | A1 |
| 20110288609 | Tehrani et al. | Nov 2011 | A1 |
| 20110295100 | Rolston et al. | Dec 2011 | A1 |
| 20120006793 | Swanson | Jan 2012 | A1 |
| 20120022551 | Staunton et al. | Jan 2012 | A1 |
| 20120029528 | Macdonald et al. | Feb 2012 | A1 |
| 20120035684 | Thompson et al. | Feb 2012 | A1 |
| 20120101326 | Simon et al. | Apr 2012 | A1 |
| 20120109251 | Lebedev et al. | May 2012 | A1 |
| 20120109295 | Fan | May 2012 | A1 |
| 20120123293 | Shah et al. | May 2012 | A1 |
| 20120126392 | Kalvesten et al. | May 2012 | A1 |
| 20120165899 | Gliner | Jun 2012 | A1 |
| 20120172946 | Altaris et al. | Jul 2012 | A1 |
| 20120179222 | Jaax et al. | Jul 2012 | A1 |
| 20120185020 | Simon et al. | Jul 2012 | A1 |
| 20120197338 | Su et al. | Aug 2012 | A1 |
| 20120203246 | Staunton et al. | Aug 2012 | A1 |
| 20120221073 | Southwell et al. | Aug 2012 | A1 |
| 20120232615 | Barolat et al. | Sep 2012 | A1 |
| 20120252874 | Feinstein et al. | Oct 2012 | A1 |
| 20120259380 | Pyles | Oct 2012 | A1 |
| 20120277824 | Li | Nov 2012 | A1 |
| 20120277834 | Mercanzini | Nov 2012 | A1 |
| 20120283697 | Kim et al. | Nov 2012 | A1 |
| 20120283797 | De Ridder | Nov 2012 | A1 |
| 20120302821 | Burnett | Nov 2012 | A1 |
| 20120310305 | Kaula et al. | Dec 2012 | A1 |
| 20120310315 | Savage et al. | Dec 2012 | A1 |
| 20120330391 | Bradley et al. | Dec 2012 | A1 |
| 20130013041 | Glukhovsky et al. | Jan 2013 | A1 |
| 20130023972 | Kuzma et al. | Jan 2013 | A1 |
| 20130030319 | Hettrick et al. | Jan 2013 | A1 |
| 20130030501 | Feler et al. | Jan 2013 | A1 |
| 20130053734 | Barriskill et al. | Feb 2013 | A1 |
| 20130066392 | Simon et al. | Mar 2013 | A1 |
| 20130085317 | Feinstein | Apr 2013 | A1 |
| 20130110196 | Alataris et al. | May 2013 | A1 |
| 20130123568 | Hamilton et al. | May 2013 | A1 |
| 20130123659 | Bartol et al. | May 2013 | A1 |
| 20130165991 | Kim et al. | Jun 2013 | A1 |
| 20130197408 | Goldfarb et al. | Aug 2013 | A1 |
| 20130253299 | Weber et al. | Sep 2013 | A1 |
| 20130253611 | Lee et al. | Sep 2013 | A1 |
| 20130268016 | Xi et al. | Oct 2013 | A1 |
| 20130268020 | Rosenberg et al. | Oct 2013 | A1 |
| 20130268021 | Moffitt | Oct 2013 | A1 |
| 20130281890 | Mishelevich | Oct 2013 | A1 |
| 20130289446 | Stone et al. | Oct 2013 | A1 |
| 20130303873 | Voros et al. | Nov 2013 | A1 |
| 20130304159 | Simon et al. | Nov 2013 | A1 |
| 20130310911 | Tai et al. | Nov 2013 | A1 |
| 20140031893 | Walker et al. | Jan 2014 | A1 |
| 20140046407 | Ben-Ezra et al. | Feb 2014 | A1 |
| 20140053401 | Kuzma et al. | Feb 2014 | A1 |
| 20140058490 | DiMarco | Feb 2014 | A1 |
| 20140066950 | Macdonald et al. | Mar 2014 | A1 |
| 20140067007 | Drees et al. | Mar 2014 | A1 |
| 20140067354 | Kaula et al. | Mar 2014 | A1 |
| 20140081071 | Simon et al. | Mar 2014 | A1 |
| 20140100633 | Mann et al. | Apr 2014 | A1 |
| 20140107397 | Simon et al. | Apr 2014 | A1 |
| 20140107398 | Simon et al. | Apr 2014 | A1 |
| 20140114374 | Rooney et al. | Apr 2014 | A1 |
| 20140163640 | Edgerton et al. | Jun 2014 | A1 |
| 20140180361 | Burdick et al. | Jun 2014 | A1 |
| 20140213842 | Simon et al. | Jul 2014 | A1 |
| 20140236257 | Parker et al. | Aug 2014 | A1 |
| 20140296752 | Edgerton et al. | Oct 2014 | A1 |
| 20140303685 | Rosenberg et al. | Oct 2014 | A1 |
| 20140303901 | Sadeh | Oct 2014 | A1 |
| 20140316484 | Edgerton et al. | Oct 2014 | A1 |
| 20140316503 | Tai et al. | Oct 2014 | A1 |
| 20140324118 | Simon et al. | Oct 2014 | A1 |
| 20140330067 | Jordan | Nov 2014 | A1 |
| 20140330335 | Errico et al. | Nov 2014 | A1 |
| 20140357936 | Simon et al. | Dec 2014 | A1 |
| 20140371830 | Howard et al. | Dec 2014 | A1 |
| 20150065559 | Feinstein et al. | Mar 2015 | A1 |
| 20150074997 | Kuzma et al. | Mar 2015 | A1 |
| 20150094734 | Staunton et al. | Apr 2015 | A1 |
| 20150165226 | Simon et al. | Jun 2015 | A1 |
| 20150182784 | Barriskill et al. | Jul 2015 | A1 |
| 20150190634 | Rezai et al. | Jul 2015 | A1 |
| 20150231396 | Burdick et al. | Aug 2015 | A1 |
| 20150265830 | Simon et al. | Sep 2015 | A1 |
| 20150343205 | Howard et al. | Dec 2015 | A1 |
| 20160030737 | Gerasimenko et al. | Feb 2016 | A1 |
| 20160030748 | Edgerton et al. | Feb 2016 | A1 |
| 20160045727 | Rezai et al. | Feb 2016 | A1 |
| 20160045731 | Simon et al. | Feb 2016 | A1 |
| 20160067477 | Dubuclet | Mar 2016 | A1 |
| 20160074663 | De Ridder | Mar 2016 | A1 |
| 20160121109 | Edgerton et al. | May 2016 | A1 |
| 20160121114 | Simon et al. | May 2016 | A1 |
| 20160121116 | Simon et al. | May 2016 | A1 |
| 20160175586 | Edgerton et al. | Jun 2016 | A1 |
| 20160213918 | Howard et al. | Jul 2016 | A1 |
| 20160220813 | Edgerton et al. | Aug 2016 | A1 |
| 20160235977 | Lu et al. | Aug 2016 | A1 |
| 20160250461 | Dubuclet | Sep 2016 | A1 |
| 20160339239 | Yoo et al. | Nov 2016 | A1 |
| 20170007831 | Edgerton et al. | Jan 2017 | A1 |
| 20170014620 | Staunton et al. | Jan 2017 | A9 |
| 20170014622 | Bozung et al. | Jan 2017 | A1 |
| 20170065814 | Howard et al. | Mar 2017 | A1 |
| 20170157389 | Tai et al. | Jun 2017 | A1 |
| 20170165497 | Lu | Jun 2017 | A1 |
| 20170246450 | Liu et al. | Aug 2017 | A1 |
| 20170274209 | Edgerton et al. | Sep 2017 | A1 |
| 20170291023 | Kuzma et al. | Oct 2017 | A1 |
| 20170296837 | Jin | Oct 2017 | A1 |
| 20180126154 | Dubuclet | May 2018 | A1 |
| 20180126155 | Mclaughlin et al. | May 2018 | A1 |
| 20180185632 | Staunton et al. | Jul 2018 | A1 |
| 20180185642 | Lu | Jul 2018 | A1 |
| 20180221651 | Chang et al. | Aug 2018 | A1 |
| 20180256906 | Pivonka et al. | Sep 2018 | A1 |
| 20180280693 | Edgerton et al. | Oct 2018 | A1 |
| 20180318576 | Bozung et al. | Nov 2018 | A1 |
| 20180361146 | Gerasimenko et al. | Dec 2018 | A1 |
| 20180369574 | Dubuclet et al. | Dec 2018 | A1 |
| 20180369575 | Dubuclet et al. | Dec 2018 | A1 |
| 20180369576 | Dubuclet et al. | Dec 2018 | A1 |
| 20190022371 | Chang et al. | Jan 2019 | A1 |
| 20190167987 | Lu et al. | Jun 2019 | A1 |
| 20190381313 | Lu | Dec 2019 | A1 |
| Number | Date | Country |
|---|---|---|
| 2012204526 | Jul 2013 | AU |
| 2 823 592 | Jul 2012 | CA |
| 2661307 | Nov 2013 | EP |
| 2968940 | Jan 2016 | EP |
| 2130326 | May 1999 | RU |
| 2141851 | Nov 1999 | RU |
| 2160127 | Dec 2000 | RU |
| 2178319 | Jan 2002 | RU |
| 2192897 | Nov 2002 | RU |
| 2001102533 | Nov 2002 | RU |
| 2226114 | Mar 2004 | RU |
| 2258496 | Aug 2005 | RU |
| 2361631 | Jul 2009 | RU |
| 2368401 | Sep 2009 | RU |
| 2387467 | Apr 2010 | RU |
| 2396995 | Aug 2010 | RU |
| 2397788 | Aug 2010 | RU |
| 2445990 | Mar 2012 | RU |
| 2471518 | Jan 2013 | RU |
| 2475283 | Feb 2013 | RU |
| WO 97047357 | Dec 1997 | WO |
| WO 03026735 | Apr 2003 | WO |
| WO 03092795 | Nov 2003 | WO |
| WO 2004087116 | Oct 2004 | WO |
| WO 2005051306 | Jun 2005 | WO |
| WO 2005087307 | Sep 2005 | WO |
| WO 2007007058 | Jan 2007 | WO |
| WO 2007107831 | Sep 2007 | WO |
| WO 2008109862 | Sep 2008 | WO |
| WO 2008121891 | Oct 2008 | WO |
| WO 2009042217 | Apr 2009 | WO |
| WO 2009111142 | Sep 2009 | WO |
| WO 2010055421 | May 2010 | WO |
| WO 2010114998 | Oct 2010 | WO |
| WO 2010124128 | Oct 2010 | WO |
| WO 2012094346 | Jul 2012 | WO |
| WO 2012100260 | Jul 2012 | WO |
| WO 2012129574 | Sep 2012 | WO |
| WO 2013071307 | May 2013 | WO |
| WO 2013071309 | May 2013 | WO |
| WO 2014144785 | Sep 2014 | WO |
| WO 2015048563 | Apr 2015 | WO |
| WO 2016029159 | Feb 2016 | WO |
| WO 2016033369 | Mar 2016 | WO |
| WO 2016033372 | Mar 2016 | WO |
| WO 2017011410 | Jan 2017 | WO |
| WO 2017024276 | Feb 2017 | WO |
| WO 2017035512 | Mar 2017 | WO |
| WO 2017044904 | Mar 2017 | WO |
| WO 2018140531 | Aug 2018 | WO |
| WO 2018217791 | Nov 2018 | WO |
| WO 2020041502 | Feb 2020 | WO |
| WO 2020041633 | Feb 2020 | WO |
| Entry |
|---|
| U.S. Office Action dated Apr. 8, 2015 issued in U.S. Appl. No. 14/355,812. |
| U.S. Final Office Action dated Sep. 21, 2015 issued in U.S. Appl. No. 14/355,812. |
| U.S. Notice of Allowance dated Apr. 13, 2016 issued in U.S. Appl. No. 14/355,812. |
| U.S. Office Action dated Oct. 18, 2016 issued in U.S. Appl. No. 15/208,529. |
| U.S. Final Office Action dated Jul. 13, 2017 issued in U.S. Appl. No. 15/208,529. |
| U.S. Office Action dated Jul. 27, 2018 issued in U.S. Appl. No. 15/208,529. |
| U.S. Final Office Action dated Apr. 19, 2019 issued in U.S. Appl. No. 15/208,529. |
| U.S. Office Action dated Oct. 3, 2017 issued in U.S. Appl. No. 15/025,201. |
| U.S. Notice of Allowance dated Aug. 1, 2018 issued in U.S. Appl. No. 15/025,201. |
| U.S. Office Action dated Jul. 13, 2016 issued in U.S. Appl. No. 14/775,618. |
| U.S. Final Office Action dated Apr. 25, 2017 issued in U.S. Appl. No. 14/775,618. |
| U.S. Notice of Allowance dated Jan. 18, 2018 issued in U.S. Appl. No. 14/775,618. |
| U.S. Office Action dated Apr. 17, 2019 issued in U.S. Appl. No. 15/344,381. |
| PCT International Search Report dated Jul. 30, 2012 issued in PCT/US2012/020112. |
| PCT International Preliminary Report on Patentability and Written Opinion dated Jul. 10, 2013 issued in PCT/US2012/020112. |
| PCT International Search Report and Written Opinion dated Mar. 19, 2013 issued in PCT/US2012/064878. |
| PCT International Preliminary Report on Patentability dated May 22, 2014 issued in PCT/US2012/064878. |
| Australian Patent Examination Report No. 1 dated Jul. 11, 2016 issued in AU 2012334926. |
| Canadian Office Action dated Aug. 31, 2018 issued in CA 2,864,473. |
| European Communication pursuant to Rule 114(2) EPC regarding observations by a third party dated Mar. 27, 2015 issued in EP 12 847 885.6. |
| European Extended Search Report dated May 6, 2015 issued in EP 12 847 885.6. |
| European Office Action dated Apr. 15, 2016 issued in EP 12 847 885.6. |
| European Reply to Communication of Apr. 15, 2016 dated Oct. 24, 2016 in EP 12 847 885.6. |
| European Second Office Action dated Feb. 16, 2017 issued in EP 12 847 885.6. |
| PCT Declaration of Non-Establishment of International Search Report and Written Opinion dated Dec. 24, 2014 issued in PCT/US2014/057886. |
| PCT International Preliminary Report on Patentability and Written Opinion dated Apr. 7, 2016 issued in PCT/US2014/057886. |
| Australian Examination report No. 1 dated Jan. 11, 2019 issued in AU 2014324660. |
| European Extended Search Report dated May 10, 2017 issued in EP 14849355.4. |
| European Office Action dated Jul. 20, 2018 issued in EP 14849355.4. |
| PCT International Search Report and Written Opinion dated Aug. 6, 2014 issued in PCT/US2014/029340. |
| PCT International Preliminary Report on Patentability dated Sep. 24, 2015 issued in PCT/US2014/029340. |
| Australian Patent Examination Report No. 1 dated May 11, 2018 issued in AU 2014228794. |
| European Extended Search Report dated Nov. 8, 2016 issued in EP 14 76 5477.6. |
| European Office Action dated Nov. 14, 2018 issued in EP 14 76 5477.6. |
| PCT International Search Report and Written Opinion dated Dec. 5, 2016 issued in PCT/US2016/045898. |
| PCT International Preliminary Report on Patentability and Written Opinion dated Feb. 15, 2018 issued in PCT/US2016/045898. |
| European Extended Search Report dated Dec. 13, 2018 issued in EP 16833973.7. |
| PCT International Search Report and Written Opinion dated Dec. 8, 2015 issued in PCT/US2015/047268. |
| PCT International Preliminary Report on Patentability and Written Opinion dated Feb. 28, 2017 issued in PCT/US2015/047268. |
| European Extended Search Report dated Mar. 1, 2018 issued in EP 15836927.2. |
| PCT International Search Report and Written Opinion dated Dec. 3, 2015 issued in PCT/US2015/047272. |
| PCT International Preliminary Report on Patentability and Written Opinion dated Feb. 28, 2017 issued in PCT/US2015/047272. |
| PCT Declaration of Non-Establishment of International Search Report and Written Opinion dated Dec. 1, 2015 issued in PCT/US2015/046378. |
| PCT International Preliminary Report on Patentability and Written Opinion dated Feb. 21, 2017 issued in PCT/US2015/046378. |
| European Extended Search Report dated Apr. 4, 2018 issued in EP 15834593.4. |
| PCT International Search Report and Written Opinion dated Sep. 12, 2016 issued in PCT/US2016/041802. |
| PCT International Preliminary Report on Patentability and Written Opinion dated Jan. 25, 2018 issued in PCT/US2016/041802. |
| European Extended Search Report dated Feb. 19, 2019 issued in EP 16825005.8. |
| PCT International Search Report and Written Opinion dated Dec. 5, 2016 issued in PCT/US2016/049129. |
| PCT International Preliminary Report on Patentability and Written Opinion dated Mar. 8, 2018 issued in PCT/US2016/049129. |
| PCT International Search Report and Written Opinion dated Mar. 12, 2018 issued in PCT/US2018/015098. |
| PCT International Search Report and Written Opinion dated Aug. 31, 2018 issued in PCT/US2018/033942. |
| PCT International Search Report dated Mar. 19, 2013 issued in PCT/US2012/064874. |
| PCT International Search Report dated Mar. 19, 2013 issued in PCT/US2012/064878. |
| PCT International Search Report dated Sep. 3, 2012 issued in PCT/US2012/022257. |
| PCT International Search Report dated Oct. 31, 2012 issued in PCT/US2012/030624. |
| Andersson, et al., (2003) “CNS Involvement in Overactive Bladder.” Drugs, 63(23): 2595-2611. |
| Angeli et al. (2014) “Altering spinal cord excitability enables voluntary movements after chronic complete paralysis in humans” Brain 137: 1394-1409. |
| Bruckenstein and Miller, (Aug. 1, 1970) “An Experimental Study of Nonuniform Current Distribution at Rotating Disk Electrodes,” Journal of The Electrochemical Society, 117: 1044-1048. |
| Chen-Chun, et al., (May 10, 2010) “Transparent microprobe array fabricated by MEMS hot embossing technology for photodynamic therapy application,” IEICE Electronics Express, 7: 569-76. |
| Courtine, Grégoire et al. (2007) “Modulation of multisegmental monosynaptic responses in a variety of leg muscles during walking and running in humans,” J Physiol. 582.3:1125-1139. |
| Danner S.M., Hofstoetter U.S., Ladenbauer J., Rattay F., and Minassian K. (Mar. 2011) “Can the human lumbar posterior columns be stimulated by transcutaneous spinal cord stimulation? A modeling study” Europe PMC Funders Author Manuscripts, Artif Organs 35(3):257-262, 12 pp. |
| DeSantana et al. (Dec. 2008) “Effectiveness of Transcutaneous Electrical Nerve Stimulation for Treatment of Hyperalgesia and Pain,” Curr Rheumatol Rep. 10(6):492-499, 12 pp. |
| Dubinsky, Richard M. and Miyasaki, Janis, “Assessment: Efficacy of transcutaneous electric nerve stimulation in the treatment of pain in neurologic disorders (an evidence-based review),” Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology, (2010) Neurology, 74:173-176. |
| Edgerton and Harkema (2011) “Epidural stimulation of the spinal cord in spinal cord injury: current status and future challenges” Expert Rev Neurother. 11(10): 1351-1353. doi:10.1586/ern.11.129 [NIH Public Access—Author Manuscript—5 pages]. |
| Fong et al. (2009) “Recovery of control of posture and locomotion after a spinal cord injury: solutions staring us in the face,” Progress in Brain Research, Elsevier Amsterdam, NL,175:393-418. |
| Ganley et al., (2005) “Epidural Spinal Cord Stimulation Improves Locomoter Performance in Low ASIA C, Wheelchair-Dependent, Spinal Cord-Injured Individuals: Insights from Metabolic Response,” Top. Spinal Cord lnj. Rehabil;11(2):50-63. |
| Gerasimenko Y., Gorodnichev R., Machueva E., Pivovarova E., Semyenov D., Savochin A., Roy R.R., and Edgerton V.R., (Mar. 10, 2010) “Novel and Direct Access to the Human Locomotor Spinal Circuitry,” J Neurosci. 30(10):3700-3708, PMC2847395. |
| Gerasimenko Y.P., Ichiyama R.M., Lavrov I.A., Courtine G., Cai L., Zhong H., Roy R.R., and Edgerton V.R. (2007) “Epidural Spinal Cord Stimulation Plus Quipazine Administration Enable Stepping in Complete Spinal Adult Rats,” J Neurophysiol. 98:2525-2536. |
| Harkema et al. (2011) “Effect of Epidural stimulation of the lumbosacral spinal cord on voluntary movement, standing, and assisted stepping after motor complete paraplegia: a case study” Lancet 377(9781): 1938-1947; NIH Public Access Author Manuscript 17 pages [doi:10.1016/S0140-6736(11)60547-3]. |
| Herman R., He J., D'Luzansky S., Willis W., Dilli S., (2002) “Spinal cord stimulation facilitates functional walking in a chronic, incomplete spinal cord injured,” Spinal Cord. 40:65-68. |
| Hofstoetter, U.S. et al. (Aug. 2008) “Modification of Reflex Responses to Lumbar Posterior Root Stimulation by Motor Tasks in Healthy Subjects,” Artif Organs, 32(8):644-648. |
| Ichiyama et al. (2005) “Hindlimb stepping movements in complete spinal rats induced by epidural spinal cord stimulation” Neuroscience Letters, 383:339-344. |
| Kitano K., Koceja D.M. (2009) “Spinal reflex in human lower leg muscles evoked by transcutaneous spinal cord stimulation,” J Neurosci Methods. 180:111-115. |
| Minasian et al. (2010) “Transcutaneous stimulation of the human lumbar spinal cord: Facilitating locomotor output in spinal cord injury,” Conf. Proceedings Soc. for Neurosci., Abstract No. 286.19, 1 page. |
| Minassian et al. (Aug. 2011) “Transcutaneous spinal cord stimulation,” International Society for Restorative Neurology, http://restorativeneurology.org/resource-center/assessments/transcutaneous-lumbar-spinal-cord-stimulation/; http://restorativeneurology.org/wp-content/uploads/2011/08/Transcutaneous-spinal-cord-stimulation_long.pdf, 6 pp. |
| Minassian et al. (Mar. 2007) “Posterior root-muscle reflexes elicited by transcutaneous stimulation of the human lumbosacral cord,” Muscle & Nerve 35:327-336. |
| Nandra et al., (2014) “Microelectrode Implants for Spinal Cord Stimulation in Rats,” Thesis, California Institute of Technology, Pasadena, California, Defended on Sep. 24, 2014, 104 pages. |
| Nandra et al., (Jan. 23, 2011) “A Parylene-Based Microelectrode Arrary Implant for Spinal Cord Stimulation in Rats,” Conf. Proc. IEEE Eng. Med. Biol. Soc., pp. 1007-1010. |
| Rodger et al., (2007) “High Density Flexible Parylene-Based Multielectrode Arrays for Retinal and Spinal Cord Stimulation,” Transducers & Eurosensors, Proc. of the 14th International Conference on Solid-State Sensors, Actuators and Microsystems, Lyon, France, Jun. 10-14, 2007, IEEE, pp. 1385-1388. |
| Rubinstein, et al., (1987) “Current Density Profiles of Surface Mounted and Recessed Electrodes for Neural Prostheses,” Biomedical Engineering, IEEE Transactions on BME, 34: 864-875. [Abstract Only—1 page]. |
| Seifert et al. (Nov. 1, 2002) “Restoration of Movement Using Functional Electrical Stimulation and Bayes' Theorem,” The Journal of Neuroscience, 22(1):9465-9474. |
| Tanabe et al. (2008) “Effects of transcutaneous electrical stimulation combined with locomotion-like movement in the treatment of post-stroke gait disorder: a single-case study,” 30(5):411-416 abstract, 1 page. |
| Tungjitkusolmun, et al., (Jan. 2000) “Finite element analyses of uniform current density electrodes for radio-frequency cardiac ablation,” Ieee Transactions on Biomedical Engineering, 47: 32-40. |
| Valchinov and Pallikarakis, (2004) “An active electrode for biopotential recording from small localized bio-sources,” BioMedical Engineering OnLine, 3:25 (14 pages). |
| Ward and Robertson, (Mar. 1998) “Sensory, motor, and pain thresholds for stimulation with medium frequency alternating current,” Archives of Physical Medicine and Rehabilitation, 79: 273-278. |
| Ward, Alex R. (Feb. 2009) “Electrical Stimulation Using Kilohertz-Frequency Alternating Current ,” (2009) Phys Ther.89(2):181-190 [published online Dec. 18, 2008]. |
| Wiley and Webster, (1982) “Analysis and Control of the Current Distribution under Circular Dispersive Electrodes,” Biomedical Engineering, IEEE Transactions on BME, 29: 381-385. |
| Yongmin and Schimpf, (1996) “Electrical behavior of defibrillation and pacing electrodes,” Proceedings of the Ieee, 84: 446-456. |
| U.S. Office Action dated Oct. 28, 2019 issued in U.S. Appl. No. 15/208,529. |
| U.S. Office Action dated Jan. 8, 2020 issued in U.S. Appl. No. 15/975,678. |
| U.S. Office Action dated Oct. 31, 2019 issued in U.S. Appl. No. 15/750,499. |
| U.S. Office Action dated Jun. 4, 2019 issued in U.S. Appl. No. 15/505,053. |
| U.S. Final Office Action dated Dec. 30, 2019 issued in U.S. Appl. No. 15/344,381. |
| Canadian Office Action dated Jul. 30, 2019 issued in CA 2,864,473. |
| Australian Examination report No. 2 dated Nov. 7, 2019 issued in AU 2014324660. |
| Australian Examination report No. 3 dated Jan. 6, 2020 issued in AU 2014324660. |
| Australian Patent Examination Report No. 1 dated Jan. 6, 2020 issued in AU 2019206059. |
| European Office Action dated Sep. 27, 2019 issued in EP 14765477.6. |
| Australian Patent Examination Report No. 1 dated Jul. 18, 2019 issued in AU 2015308779. |
| Australian Patent Examination Report No. 1 dated Jun. 14, 2019 issued in AU 2015305237. |
| European Office Action dated Jul. 17, 2019 issued in EP 15834593.4. |
| PCT International Preliminary Report on Patentability and Written Opinion dated Jul. 30, 2019 issued in PCT/US2018/015098. |
| PCT International Preliminary Report on Patentability and Written Opinion dated Nov. 26, 2019 issued in PCT/US2018/033942. |
| Kapetanakis, et al. (2017) “Cauda Equina Syndrome Due to Lumbar Disc Herniation: a Review of Literature,” Folia Medica, 59(4): 377-86. |
| Wang, et al. (2017) “Incidence of C5 nerve root palsy after cervical surgery,” Medicine, 96(45), 14 pages. |
| U.S. Office Action dated Apr. 10, 2020 issued in U.S. Appl. No. 16/200,467. |
| U.S. Notice of Allowance dated Feb. 13, 2020 issued in U.S. Appl. No. 15/505,053. |
| European Extended Search Report dated Apr. 21, 2020 issued in EP 19201998.2. |
| Australian Patent Examination Report No. 2 dated Apr. 17, 2020 issued in AU 2015305237. |
| PCT International Search Report and Written Opinion dated Nov. 14, 2019 issued in PCT/US2019/047777. |
| PCT International Search Report and Written Opinion dated Nov. 21, 2019 issued in PCT/US2019/047551. |
| Number | Date | Country | |
|---|---|---|---|
| 20170246452 A1 | Aug 2017 | US |
| Number | Date | Country | |
|---|---|---|---|
| 62042672 | Aug 2014 | US | |
| 62171427 | Jun 2015 | US |
